Antiviral indolinyl compounds and uses thereof

HK40137380APending Publication Date: 2026-09-11GILEAD SCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124876
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-17
Filing Date
2026-06-16
Publication Date
2026-09-11
Patent Text Reader

Abstract

The present disclosure relates to indolinyl compounds. The disclosure further relates to compounds that inhibit a viral helicase-elicitor enzyme. The disclosure further relates to the use of the compound for the preparation of a medicament for the treatment of diseases and / or conditions by inhibition of the viral helicase-eliciting enzyme. The disclosure also relates to the use of those compounds in the treatment of viral infections. The disclosure further relates to intermediates useful in their preparation and pharmaceutical compositions containing those compounds. (I)
Need to check novelty before this filing date? Find Prior Art

Description

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 May 2025 (22.05.2025) Shān Shān Cè Cè Shān Jī Nǎ Cè Cè Cè Quán Jiā M (10) International Publication Number WO 2025 / 107003 A1 WIPO I PCT (51) International Patent Classification: C07D 405 / 14 (2006.01) A61P 31 / 12 (2006.01) C07D 401 / 10 (2006.01) A61K 31 / 403 (2006.01) (21) International Application Number: PCT / US2024 / 056433 (22) International Filing Date: 18 November 2024 (18.11.2024) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 63 / 600,138 17 November 2023 (17.11.2023) US (71) Applicant: GILEAD SCIENCES, INC. [US / US]; 333 Lakeside Drive, Foster City, California 94404 (US). (72) Inventors: CHO, Aesop; c / o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). STRATTON, Thomas P.; c / o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). (74) Agent:FIX, Amy H. et al.; Barnes & Thornburg LLP, 4208 Six Forks Road, Suite 1010, Raleigh, North Carolina 27609 (US). (84) Designated States (unless otherwise indicated, far every kind of regional protection available)'. ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published:—— with international search report (Art. 21 — before the expiration of the time limit far amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (81) Designated States (unless otherwise indicated, far every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK,DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY MA, MD, MG, MK, MN, MU, MW, MX, MX MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SY SY TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. (54) Title: ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF (57) Abstract: The present disclosure relates to indolinyl compounds. The present disclosure further relates to compounds that inhibit viral helicase-pri- mase. The present disclosure further relates to the use of the compounds for the preparation a medicament for the treatment of diseases and / or condition through inhibiting viral helicase-primase. The present disclosure also relates to use of those compounds in the treatment of viral infections. The present disclosure further relates to intermediates for its preparation and to pharma¬ ceuticalcompositions containing those compounds. =_ -= =-== == == == == === WO 2025 / 107003 PCT / US2024 / 056433 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 600,138, filed November 17, 2023, which is incorporated by reference in its entirety. FIELD

[0002] The present disclosure relates to indolinyl compounds. The present disclosure also relates to use of those compounds in the treatment of viral infections. The present disclosure further relates to intermediates for its preparation and to pharmaceutical compositions containing those compounds. BACKGROUND

[0003] Herpesviruses have a very high global prevalence and disease burden. Herpesvirues include herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella-zoster virus, Epstein-Barr virus, and cytomegalovirus. HSV-1 and HSV-2 are contagious human pathogens. HSV-1 is mainly transmitted by oral-to-oral contact tocause oral herpes, while HSV-2 is a sexually transmitted infection that causes genital herpes. These infections are lifelong and characterized by periodic re-activation and viral shedding, which can cause symptoms such as painful blisters or ulcers and transmissions to others. Currently available medications to treat these infections are largely based on nucleoside analogs such as acyclovir, famciclovir, and valacyclovir. Although effective at reducing severity and frequency of the symptoms, these compounds do not eliminate viral shedding and thus a risk of transmission. In addition, dosing regimens are complex and inconvenient.

[0004] Herpesvirus encodes its own helicase and primase for synthesis of viral DNA. The helicase-primase complex performs a key role in viral DNA replication. The helicase separates the viral DNA double helix, and the primase synthesizes RNA primers on the single-stranded DNA which initiates DNA synthesis directed by the DNA polymerase (Kleymann G. 2004).

[0005] There is a need for new agents that are more effective and safer with improved pharmacokinetics. Inhibition of viral helicase-primase interferes with viral replication and thus 1 (19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480072956.4 (22) Application Date 2024.11.18 (30) Priority Data 63 / 600,138 2023.11.17 US (85) PCT International Application Entering National Phase Date 2026.05.15 (86) PCT International Application Application Data PCT / US2024 / 056433 2024.11.18 (87) PCT International Application Publication Data WO2025 / 107003 EN 2025.05.22 (71) Applicant: Gilead Sciences, Inc. Address: California, USA (72) Inventor: A. Joe T. P. Stratton (74) Patent Agency: King & Wood Mallesons, Beijing 11256 Patent Attorney: Ma Hui (51) Int.Cl. C07D 405 / 14 (2006.01) C07D 401 / 10 (2006.01) A61P 31 / 12 (2006.01) A61K 31 / 403 (2006.01) (54) Invention Title: Antiviral Indoline Compounds and Their Use (57) Abstract: This disclosure relates to indoline compounds. This disclosure further relates to compounds that inhibit viral helicase-initiating enzymes. This disclosure further relates to the use of the compounds in the preparation of medicaments for treating diseases and / or conditions by inhibiting viral helicase-initiating enzymes. This disclosure also relates to the use of those compounds in the treatment of viral infections. This disclosure further relates to intermediates used in their preparation and pharmaceutical compositions containing those compounds. (I) Claims 6 pages, Description 60 pages, CN 122206672 A 2026.06.12 CN 1 22 20 66 72 A 1. A compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1 is, or; R2a, R2b and R2c are each independently H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, -CN, C1-6 haloalkoxy or -SCF3; R3a and R3b are each independently H, halogen, C1-6 alkyl or C1-6 haloalkyl;Xa and Xb are each independently O or CR7aR7b; each R7a is independently H, C1-6 alkyl, or C1-6 haloalkyl; each R7b is independently H, C1-6 alkyl, or C1-6 haloalkyl; R4a, R4b, and R4c are each independently H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, -CN, -SCF3, or optionally C3-6 cycloalkyl substituted with Z4; R5 is C6-10 aryl or heteroaryl; wherein the aryl or heteroaryl of R5 is optionally substituted by one to three Z5 atoms that are the same or different; the heteroaryl of R5 is a 5- to 10-membered heteroaryl having one to three heteroatoms that are each independently N, O, or S; R6 is H, C1-6 alkyl, C1-6 haloalkyl, C2-8 alkoxyalkyl, or C3-6 cycloalkyl, wherein the cycloalkyl group of R6 is optionally substituted by one to three Z6 groups; R8 is NHR9 or NR9R10; each R9, R10, and R12 is independently C1-6 alkyl, C1-6 haloalkyl, -COR9a, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R9, R10, or R12 is optionally substituted by one to three groups independently selected from -OR12a and -SR12a; R11 is H, C1-6 alkyl, C1-6 haloalkyl, -COR9a, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R11 is optionally substituted by one to three groups each independently selected from -OR12a or -SR12a; each R13 and R14 is independently H or C1-6 alkyl; R15 is a C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R15 is optionally substituted by one to three groups, each independently of -OR12a or -SR12a; each R9a and R12a is independently C1-6 alkyl; and each Z4, Z5, and Z6 is independently halogen, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy; provided that R12 is not -CH3 when R11 is H. 2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (Ia): Claims 1 / 6 page 2 CN 122206672 A (Ia). 3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (II): (II). 4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIa): (IIa). 5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (III): (III). 6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (III).(IIIa) represents: (IIIa). 7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIIb): Claims 2 / 6 Page 3 CN 122206672 A (IIIb). 8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIIc): (IIIc). 9. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIId): (IIId). 10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIIe): (IIIe). 11. The compound of any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, wherein R2a is H. 12. The compound of any one of claims 1 to 8 and 11 or a pharmaceutically acceptable salt thereof, wherein R2b is a halogen. 13. The compound of any one of claims 1 to 8 and 11 or a pharmaceutically acceptable salt thereof, wherein R2b is F. 14. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and 11 to 13, wherein R2c is H. 15. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 and 11 to 14, wherein R3a is H. 16. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 and 11 to 15, wherein R3b is H. 17. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and 11 to 16, wherein R4a is H. 18. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and 11 to 17, wherein R4b is H. 19. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and 11 to 18, wherein R4c is H. 20. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 and 11 to 22, wherein R5 is a heteroaryl group; wherein the heteroaryl group of R5 is optionally substituted with one to three Z5 groups that are identical or different. 21. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 and 11 to 20, wherein R5 is a pyridyl group optionally substituted with one to three Z5 groups that are identical or different. 22. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 and 11 to 21, wherein R5 is a pyridyl group. 23. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 22, wherein R6 is H, C1-6.24. The compound of any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof, wherein R6 is H. 25. The compound of any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof, wherein R6 is -CH3. 26. The compound of any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof, wherein R1 is... 27. The compound of any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof, wherein R1 is...; R8 is NHR9 or NR9R10; each R9 and R10 is independently a C1-6 alkyl, C1-6 haloalkyl, -COR9a, or C3-6 cycloalkyl; the C1-6 alkyl group of R9 or R10 is optionally substituted with -OR12a; and each R9a and R12a is independently a C1-6 alkyl. 28. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R1 is; R8 is NHR9; R9 is C1-6 alkyl or -COR9a; and R9a is C1-6 alkyl. 29. The compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof, wherein R1 is or . 30. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R1 is . 31. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R1 is; R11 is H; R12 is -CH2OR12a, C2-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R12 is optionally substituted with -OR12a; and R12a is C1-6 alkyl. 32. The compound of any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof, wherein R1 is ; R11 is H; R12 is a C2-6 alkyl or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R12 is optionally substituted with -OR12a; and R12a is a C1-6 alkyl. 33. The compound of any one of claims 1 to 25 and 30 to 32 or a pharmaceutically acceptable salt thereof, wherein R1 is , , or . 34. The compound of any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof, wherein R1 is ; R11 is a C1-6 alkyl; R12 is a C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R12 is optionally substituted with -OR12a; and R12a is a C1-6 alkyl. 35. The compound of any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof, wherein R1 is ; R11 is a C1-6 alkyl;R12 is a C1-6 alkyl or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R12 is optionally substituted with -OR12a; and R12a is a C1-6 alkyl. 36. A compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 25, 30, 34 and 35, wherein R1 is... 37. A compound from Table 1 or a pharmaceutically acceptable salt thereof. 38. A compound from Table 1 or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a mixture of stereoisomers thereof. 39. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 and at least one pharmaceutically acceptable carrier. 40. The pharmaceutical composition according to claim 39, further comprising one, two, three or four additional therapeutic agents. 41. The pharmaceutical composition according to claim 40, wherein the additional therapeutic agent is selected from famciclovir, acyclovir, and valacyclovir. 42. A method for treating herpesvirus infection, the method comprising administering to a patient a therapeutically effective amount of the compound of any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof, or administering to a patient in need a therapeutically effective amount of the composition of any one of claims 39 to 41. (Claims 5 / 6, page 6, CN 122206672 A) 43. The method of claim 42, wherein the method comprises administering a combination of the compound of any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof, or the composition of any one of claims 39 to 41, with one, two, three, or four additional therapeutic agents. 44. The method of claim 42 or 43, wherein the herpesvirus is HSV-1 or HSV-2. 45. A method for treating a disorder induced, aggravated, or accelerated by a herpesvirus, the method comprising administering to a patient a therapeutically effective amount of the compound of any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof, or administering to a patient in need a therapeutically effective amount of the composition of any one of claims 39 to 41. 46. ​​The method of claim 45, wherein the method comprises administering a compound of any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof, or a composition of any one of claims 39 to 41, in combination with one, two, three, or four additional therapeutic agents. 47. The method of claim 45 or 46, wherein the barrier is genital herpes, cold sores, HSV keratitis, HSV encephalitis, or disseminated HSV. 48. Use of a compound of any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof in the treatment of viral infections. 49. Use of a compound of any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof in the treatment of viral infections caused by herpesviruses.50. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 in the treatment of viral infections caused by HSV-1 or HSV-2. 51. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 in the preparation of a medicament for the prevention / treatment of viral infections. 52. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 in the preparation of a medicament for the prevention / treatment of viral infections caused by herpesviruses. 53. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 in the preparation of a medicament for the prevention / treatment of viral infections caused by HSV-1 or HSV-2. 54. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38, or the pharmaceutical composition according to any one of claims 39 to 41, used in a method of treating viral infections caused by HSV-1 or HSV-2. 55. The compound, its pharmaceutically acceptable salt, or pharmaceutical composition used according to claim 54, wherein the viral infection is genital herpes, cold sores, HSV keratitis, HSV encephalitis, or disseminated HSV. 56. The compound, its pharmaceutically acceptable salt, or pharmaceutical composition used according to claim 54 or 55, wherein the compound or its pharmaceutically acceptable salt is administered in combination with an additional therapeutic agent. 57. The compound or its pharmaceutically acceptable salt used according to any one of claims 1 to 38, wherein the compound or its pharmaceutically acceptable salt is used in a therapeutic manner. Claims 6 / 6 Page 7 CN 122206672 A Cross-Reference to Related Applications Regarding Antiviral Indoline Compounds and Their Use

[0001] This application claims priority to U.S. Provisional Application No. 63 / 600,138, filed November 17, 2023, the entire contents of which are incorporated herein by reference. Technical Field

[0002] This disclosure relates to indoline compounds. This disclosure also relates to the use of those compounds in the treatment of viral infections. This disclosure further relates to intermediates used in their preparation and pharmaceutical compositions containing those compounds. Background Art

[0003] Herpesviruses have a very high global prevalence and disease burden. Herpesviruses include herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), varicella-zoster virus, Epstein-Barr virus, and cytomegalovirus. HSV-1 and HSV-2 are infectious human pathogens. HSV-1 is primarily transmitted through oral-oral contact and causes oral herpes, while HSV-2 is a sexually transmitted infection that causes genital herpes. These infections are lifelong and characterized by periodicity.The reactivation and shedding of the virus can cause symptoms such as painful blisters or ulcers and spread to others. Currently available drugs for treating these infections are mainly based on nucleoside analogs, such as acyclovir, famciclovir, and valacyclovir. Although these compounds are effective in reducing the severity and frequency of symptoms, they do not eliminate viral shedding and therefore do not eliminate the risk of transmission. In addition, the administration regimens are complex and inconvenient.

[0004] Herpesviruses encode their own helicases and primases for synthesizing viral DNA. The helicase-primase complex plays a key role in viral DNA replication. The helicase separates the viral DNA double helix, and the primase synthesizes RNA primers on single-stranded DNA, thereby initiating DNA synthesis directed by DNA polymerase (Kleymann G. 2004).

[0005] There is a need for new agents that are more effective, safer, and have improved pharmacokinetics. Inhibition of viral helicase-primase interferes with viral replication, thus potentially leading to the development of drugs with desired selectivity, potency, metabolic stability, or reduced adverse effects.

[0006] This disclosure relates to indolinel compounds. This disclosure also relates to compounds that inhibit viral helicase-initiator enzymes. This disclosure further relates to the use of these compounds for the treatment and / or prevention of diseases and / or conditions.

[0007] In one embodiment, compounds of formula (I) are provided herein: (I) or a pharmaceutically acceptable salt thereof, wherein R1 is, or; R2a, R2b and R2c are each independently H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, -CN, C1-6 haloalkoxy or -SCF3; R3a and R3b are each independently H, halogen, C1-6 alkyl or C1-6 haloalkyl; Xa and Xb are each independently O or CR7aR7b; each R7a is independently H, C1-6 alkyl or C1-6 haloalkyl; each R7b is independently H, C1-6 alkyl or C1-6 haloalkyl; R4a, R4b, and R4c are each independently H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, -CN, -SCF3, or C3-6 cycloalkyl optionally substituted with Z4; R5 is C6-10 aryl or heteroaryl; wherein the aryl or heteroaryl group of R5 is optionally substituted with one to three Z5 groups that are identical or different; the heteroaryl group of R5 is a 5- to 10-membered heteroaryl group having one to three heteroatoms that are independently N, O, or S; R6 is H, C1-6 alkyl, C1-6 haloalkyl, C2-8 alkoxyalkyl, or C3-6 cycloalkyl, wherein the cycloalkyl group of R6 is optionally substituted with one to three Z6 groups; R8 is NHR9 or NR9R10;Each of R9, R10, and R12 is independently a C1-6 alkyl, C1-6 haloalkyl, -COR9a, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R9, R10, or R12 is optionally substituted with one to three groups independently selected from -OR12a and -SR12a; R11 is H, C1-6 alkyl, C1-6 haloalkyl, -COR9a, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R11 is optionally substituted with one to three groups each independently selected from -OR12a or -SR12a; each of R13 and R14 is independently H or C1-6 alkyl; R15 is C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R15 is optionally substituted with one to three groups each independently selected from -OR12a or -SR12a; Each R9a and R12a is independently C1-6 alkyl; and each Z4, Z5, and Z6 is independently halogen, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy; provided that R12 is not -CH3 when R11 is H.

[0008] In some embodiments, pharmaceutical compositions are provided herein comprising a compound provided herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

[0009] In some embodiments, the pharmaceutical compositions provided herein further comprise one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical composition further comprises a therapeutically effective amount of one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents or pharmaceutically acceptable salts thereof.

[0010] In some embodiments, this disclosure provides methods for inhibiting the helicase-initiator enzyme of herpesviruses in a subject in need, methods comprising administering to the subject a therapeutically effective amount of a compound provided herein (e.g., a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe)) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein. Specification 2 / 60 pages 9 CN 122206672 A

[0011] In some embodiments, this disclosure provides methods for treating a patient suffering from a herpesvirus-mediated condition, methods comprising administering to the patient a therapeutically effective amount of a compound provided herein (e.g., a compound of formula (I), (Ia), (II), (IIa)).Compounds of (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or pharmaceutically acceptable salts thereof, or pharmaceutical compositions provided herein. Detailed Description

[0012] This disclosure relates to compounds that inhibit the helicase priming enzyme of herpesviruses. In one embodiment, this disclosure relates to indolinel compounds. This disclosure further relates to the use of these compounds for the treatment and / or prevention of diseases and / or conditions by means of said compounds. This disclosure also relates to compositions and methods for treating and / or preventing viral infections comprising a combination of a herpesvirus helicase priming enzyme inhibitor and one or more additional therapeutic agents.

[0013] Patients infected with herpesviruses may benefit from treatment with a herpesvirus helicase priming enzyme inhibitor and optionally one or more additional therapeutic agents.

[0014] Definitions and General Parameters As described below, this disclosure is to be understood as illustrative of the claimed subject matter and is not intended to limit the appended claims to the specific embodiments illustrated. The headings used throughout this disclosure are provided for convenience and should not be construed as limiting the claims in any way. The embodiments illustrated under any heading may be combined with the embodiments illustrated under any other heading.

[0015] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. It must be noted that, as used herein and in the appended claims, the singular forms “an,” “a,” and “the” include plural referents unless the context clearly specifies otherwise. Thus, for example, reference to “compound” includes a variety of such compounds, and reference to “assay” includes reference to one or more assays known to one of those skilled in the art and their equivalents, etc.

[0016] As used herein, the following terms and phrases are generally intended to have the meanings described below unless the context of their use indicates otherwise.

[0017] A dash (“-”) not between two letters or symbols is used to indicate the attachment point of a substituent. For example, -CONH2 is attached by a carbon atom. A dash at the front or end of a chemical group is for convenience; a chemical group may be depicted without one or more dashes without losing its ordinary meaning. A wavy line drawn through a line in the structure indicates the attachment point of a group. Unless required by chemistry or structure, the order in which chemical groups are written or named does not indicate or imply directionality. A solid line extending from the center of the ring indicates that the attachment point of a substituent on the ring can be at any ring atom. For example, Ra in the following structures can be attached to any of the five carbon ring atoms, or Ra can replace hydrogen attached to a nitrogen ring atom:

[0018] The prefix "Cu-v" indicates that the following groups have u to v carbon atoms. For example, "C1-6 alkyl" indicates that the alkyl group has 1Up to 6 carbon atoms. Similarly, the term "x-y member" ring (where x and y are numerical ranges, such as "3 to 12 membered heterocyclic group") refers to a ring containing x-y atoms (e.g., 3-12), of which up to 80% may be heteroatoms, such as N, O, S, P, and the remaining atoms are carbon.

[0019] Moreover, certain commonly used alternative chemical names may or may not be used. For example, divalent groups (such as divalent "alkyl" groups, divalent "aryl" groups, etc.) may also be referred to as "alkylene" groups or "arylene" groups, respectively.

[0020] "Compounds disclosed herein" or "Compounds provided herein" or "Compounds described herein" (page 3 / 60, CN 122206672 A) refers to compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe). Specific compounds provided herein are also included.

[0021] The “about” value or parameter mentioned herein includes (and describes) embodiments relating to the value or parameter itself. In some embodiments, the term “about” includes an indicated amount ±10%. In other embodiments, the term “about” includes an indicated amount ±5%. In some other embodiments, the term “about” includes an indicated amount ±1%. Furthermore, the term “about X” includes a description of “X”. Moreover, unless the context clearly specifies otherwise, the singular forms “a” and “the” include plural references. Thus, for example, reference to “compound” includes a variety of such compounds, and reference to “determination” includes reference to one or more determinations and their equivalents known to those skilled in the art.

[0022] “Alkyl” refers to a saturated hydrocarbon chain that is unbranched or branched. As used herein, an alkyl group has 1 to 20 carbon atoms (i.e., C1-20 alkyl), 1 to 8 carbon atoms (i.e., C1-8 alkyl), 1 to 6 carbon atoms (i.e., C1-6 alkyl), 1 to 4 carbon atoms (i.e., C1-4 alkyl), or 1 to 3 carbon atoms (i.e., C1-3 alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue with a specific number of carbons is named by a chemical name or identified by a molecular formula, it can encompass all positional isomers having that number of carbons; thus, for example, "butyl" includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3); and "propyl" includes n-propyl (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).

[0023] "Alkenyl" refers to an aliphatic group containing at least one carbon-carbon double bond and having 2 to 20 carbon atoms (i.e., C2-20 alkenyl), 2 to 8 carbon atoms (i.e., C2-8 alkenyl), 2 to 6 carbon atoms (i.e., C2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C2-4 alkenyl). Examples of alkenyl groups include vinyl, propenyl, and butadienyl (including 1,2-butadienyl and 1,3-butadienyl).

[0024] "Alynyl" refers to an aliphatic group containing at least one carbon-carbon triple bond and having 2 to 20 carbon atoms (i.e., C2-20 alynyl), 2 to 8 carbon atoms (i.e., C2-8 alynyl), 2 to 6 carbon atoms (i.e., C2-6 alynyl), or 2 to 4 carbon atoms (i.e., C2-4 alynyl). The term "alkynyl" also includes those groups having one triple bond and one double bond.

[0025] “Acyl” means a group -C(O)R, wherein R is hydrogen, alkyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each of these may optionally be substituted, as defined herein. Examples of acyl groups include formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.

[0026] “Alkoxy” means an alkyl group having an oxygen atom attached to the alkyl group at the attachment point: alkyl-O-. Like alkyl groups, alkoxy groups will have any suitable number of carbon atoms, such as C16. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 2-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, etc. Alkoxy groups may be further substituted by a variety of substituents described herein. Alkoxy groups may be substituted or unsubstituted.

[0027] “Alkoxyalkyl” means an alkoxy group attached to an alkyl group that is attached to the remainder of the compound. The alkoxyalkyl group has any suitable number of carbons, such as 2 to 6 (C2-6 alkoxyalkyl), 2 to 5 (C2-5 alkoxyalkyl), 2 to 4 (C2-4 alkoxyalkyl), or 2 to 3 (C2-3 alkoxyalkyl). The number of carbons refers to the total number of carbons in the alkoxy and alkyl groups. For example, in some embodiments, C6 alkoxyalkyl means ethoxy (C2 alkoxy) linked to butyl (C4 alkyl) and in other embodiments, n-propoxy (C3 alkoxy) linked to isopropyl (C3 alkyl). Alkoxy and alkyl groups are as defined above, wherein the alkyl group is divalent and may include, but is not limited to, methoxymethyl (CH3OCH2), methoxyethyl (CH3OCH2CH2), etc.

[0028] "Amino" means the group NRyRz, wherein Ry and Rz are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclic; each of which may optionally be substituted. Instruction manual, page 4 / 60, 11 CN 122206672 A

[0029] As used herein, “aryl” refers to a single all-carbon aromatic ring or a polycyclic all-carbon ring system, wherein at least one ring is aromatic. For example, in some embodiments, the aryl group has 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 12 carbon atoms. Aryl groups include phenyl radicals. Aryl groups also include polycyclic ring systems (e.g., ring systems containing 2, 3, or 4 rings) having 9 to 20 carbon atoms (e.g., 9 to 16 carbon atoms), wherein at least one ring is aromatic and the other rings may be aromatic or non-aromatic (i.e., carbon rings). Such polycyclic ring systems may optionally have one or more (e.g., 1, 2, or 3) oxo groups substituted on any carbon ring portion of the polycyclic ring system. When valence requirements permit, the rings of a polycyclic ring system may be linked to each other via fusion, spirocyclic, and bridging bonds. It should also be understood that when referring to a range of aryl groups (e.g., 6-10 aryl groups), the range of atoms is the total number of ring atoms of that aryl group. For example, a 6-aryl group would include phenyl, and a 10-aryl group would include naphthyl and 1,2,3,4-tetrahydronaphthyl. Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracene, etc.

[0030] “Cyano” or “formonitrile” refers to the group CN.

[0031] “Cycloalkyl” refers to a saturated or partially saturated cyclic alkyl group having a single ring or including multiple rings of fused, bridged, and spirocyclic systems. The term “cycloalkyl” includes cycloalkenyl groups (i.e., cyclic groups having at least one double bond). As used herein, cycloalkyl groups have 3 to 20 cyclic carbon atoms (i.e., C3-20 cycloalkyl), 3 to 12 cyclic carbon atoms (i.e., C3-12 cycloalkyl), 3 to 10 cyclic carbon atoms (i.e., C3-10 cycloalkyl), 3 to 8 cyclic carbon atoms (i.e., C3-8 cycloalkyl), or 3 to 6 cyclic carbon atoms (i.e., C3-6 cycloalkyl). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0032] “Fused” refers to a ring bonded to an adjacent ring. In some embodiments, the fused ring system is a heterocyclic group. In some embodiments, the fused ring system is an oxabiscyclohexyl group. In some embodiments, the fused ring system is or.

[0033] “Bridged” refers to ring fusion in which non-adjacent atoms on the ring are linked by a divalent substituent (such as an alkylene group, an alkylene group containing one or two heteroatoms) or a single heteroatom. Quinine cycloalkyl and adamantyl are examples of bridged ring systems. In some embodiments, the bridging ring is a bicyclopentyl (e.g., bicyclo[1.1.1]pentyl), a bicyclohepyl (e.g., bicyclo[2.2.1]hepyl, bicyclo[3.1.1]hepyl), or a bicyclooctyl (e.g., bicyclo[2.2.2]octyl). In some embodiments, the bridging ring is , , , or .

[0034] "spiro" refers to a cyclic substituent connected by two bonds at the same carbon atom. Examples of spiro groups include 1,1-diEthylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4-methylpiperidine, wherein cyclopentane and piperidine are spiro-substituents, respectively. In some embodiments, the spiro-substituent is spiropentyl (spiro[a.b]pentyl), spirohexyl, spiropentyl, spirooctyl (e.g., spiro[2.5]octyl), spiropentyl (e.g., spiro[3.5]nonyl), spiropentyl (e.g., spiro[4.5]decyl), or spiropentyl (e.g., spiropentyl[5.5]undecyl). In some embodiments, the spiro-substituent is, , or.

[0035] “halogen” or “halogroup” includes fluorine, chlorine, bromine, and iodine.

[0036] As used herein, “haloalkyl” means an alkyl group as defined herein, wherein one or more hydrogen atoms of the alkyl group are independently replaced by a halosubstituent, which may be the same or different. For example, a C1-4 haloalkyl is a C1-4 alkyl group in which one or more hydrogen atoms of the hydrogen atoms of the C1-4 alkyl group have been replaced by a halosubstituent. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, fluorochloromethyl, difluoromethyl, difluorochloromethyl, trifluoromethyl, 1,1,1-trifluoroethyl, and pentafluoroethyl.

[0037] "Haloalkoxy" refers to an alkoxy group in which some or all of its hydrogen atoms are replaced by halogen atoms. Like alkyl groups, haloalkoxy groups can have any suitable number of carbon atoms, such as C16. Alkoxy groups can be replaced by one, two, three, or more halogens. When all hydrogens are replaced by halogens (e.g., fluorine), the compound is fully substituted, such as perfluorinated. Haloalkoxy groups include, but are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, perfluoroethoxy, etc.

[0038] As used herein, the term "heteroaryl" refers to a single aromatic ring or a polycyclic ring. This term includes monoaryl rings having about 1 to 6 carbon atoms and about 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. Sulfur and nitrogen atoms may also be present in oxidized forms, provided the ring is aromatic. Such rings include, but are not limited to, pyridinyl, pyrimidinyl, oxazolyl, or furanyl. This term also includes polycyclic systems (e.g., systems comprising 2 or 3 rings) in which a heteroaryl group as defined above may be fused with one or more heteroaryl groups (e.g., naphthidyl), carbocyclic rings (e.g., 5,6,7,8-tetrahydroquinolinyl), or aryl groups (e.g., indazolyl) to form a polycyclic ring. Such polycyclic rings may optionally be substituted with one or more (e.g., 1, 2, or 3) oxo groups on the carbocyclic portion of the polycyclic ring. It should be understood that the attachment point of a heteroaryl polycyclic ring as defined above can be at any position on the ring, including the heteroaryl, aryl, or carbocyclic portion of the ring. Exemplary heteroaryl groups include, but are not limited to, pyridyl, pyrroloyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thiophenyl, indolyl, imidazolyl, oxazolyl, thiazolyl, furanyl, and oxadiazolyl.Azolyl, thiadiazolyl, quinolinyl, isoquinolinyl, benzothiazolyl, benzoxazolyl, indazole, quinoxalinyl, quinazolinyl, 5,6,7,8-tetrahydroisoquinolinylbenzofuranyl, benzimidazolyl, and thionyl.

[0039] As used herein, "heterocyclic group" or "heterocyclic ring" or "heterocycle" refers to a monosaturated or partially unsaturated ring or polycyclic ring. The term includes monosaturated or partially unsaturated rings (e.g., 3, 4, 5, 6, or 7-membered rings) containing about 1 to 6 carbon atoms and about 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. The ring may be substituted by one or more (e.g., 1, 2, or 3) oxo groups, and the sulfur and nitrogen atoms may also be present in their oxidized forms. Such rings include, but are not limited to, nitrogen-containing heterocyclic butyl, tetrahydrofuranyl, or piperidinyl. The term also includes polycyclic systems (e.g., cyclic systems containing 2 or 3 rings), wherein a heterocyclic group (as defined above) can be attached to two adjacent atoms via one or more heterocycles (e.g., decahydronaphthyl), heteroaryl (e.g., 1,2,3,4-tetrahydronaphthidyl), carbocyclic (e.g., decahydroquinolinyl), or aryl (fused heterocycle). It should be understood that the attachment point of a heterocyclic polycyclic ring as defined above can be at any position on the ring, including the heterocyclic, heteroaryl, aryl, or carbocyclic portion of the ring. Exemplary heterocycles include, but are not limited to, aziridinyl, aziridine, pyrrolidine, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazine, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,2,3,4-tetrahydroquinolinyl, benzoxazine, dihydrooxazolyl, benzodihydropyranyl, 1,2-dihydropyridinyl, 2,3-dihydrobenzofuranyl, 1,3-benzo-m-dioxacyclopentenyl, and 1,4-benzodioxacyclohexyl. Exemplary fused bicyclic heterocycles include, but are not limited to, page 6 / 60 of the specification, CN 122206672 A, ...

[0041] “Oxo-group” refers to a group (=O) or (O).

[0042] “Sulfoyl group” refers to a group S(O)2Rc, wherein Rc is an alkyl, heterocyclic, cycloalkyl, heteroaryl, or aryl group. Examples of sulfonyl groups are methanesulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.

[0043] Unless otherwise stated, whenever the graphical representation of a group terminates at a single-bonded nitrogen atom, the group represents an -NH2 group. Similarly, unless otherwise expressed, hydrogen atoms are implied and assumed to be present where necessary, based on knowledge of valence or stability provided by those skilled in the art.

[0044] The terms “optional” or “optionally” mean that the events or conditions described below may or may not occur, and the description includes instances where said events or conditions occur and instances where said events or conditions do not occur.Furthermore, the term "optionally substituted" means that any one or more hydrogen atoms on the specified atom or group may be substituted with a portion other than hydrogen, or may not be substituted with a portion other than hydrogen.

[0045] The term "substituted" means that any one or more hydrogen atoms on the specified atom or group are substituted with one or more substituents other than hydrogen, provided that the substitution does not exceed the normal valence of the specified atom. One or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amide, amidyl, aryl, azide, carbamoyl, carboxyl, carboxyl ester, cyano, guanidinyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclic, hydroxyl, hydrazyl, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thion, or combinations thereof. Polymers or similar indeterminate structures obtained by defining substituents with an unlimited number of additional substituents (e.g., substituted aryl groups with substituted alkyl groups, the substituted alkyl group itself being substituted by a substituted aryl group, the substituted aryl group being further substituted by a substituted heteroalkyl group, etc.) are not intended to be included herein. Unless otherwise stated, the maximum number of successive substitutions in the compounds described herein is three. For example, successive substitution of a substituted aryl group by two other substituted aryl groups is limited to [(substituted aryl) substituted aryl] substituted aryl. Similarly, the above definitions are not intended to include permissible substitution patterns (e.g., methyl groups substituted with five fluorine atoms or heteroaryl groups having two adjacent oxygen ring atoms). Such permissible substitution patterns are well known to those skilled in the art. When used to modify chemical groups, the term "substituted" may describe other chemical groups as defined herein. For example, the term "substituted aryl" includes, but is not limited to, "alkylaryl". Unless otherwise stated, groups are described as optionally substituted, and any substituents in these groups are themselves unsubstituted.

[0046] In some embodiments, the term "substituted alkyl" refers to an alkyl group having one or more substituents, including hydroxyl, haloalkyl, amino, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl. In other embodiments, "substituted cycloalkyl" refers to a cycloalkyl group having one or more substituents, including alkyl, haloalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, amino, alkoxy, haloalkyl, oxo, and hydroxyl; "substituted heterocyclic" refers to a heterocyclic group having one or more substituents, including alkyl, amino, haloalkyl, heterocyclic, cycloalkyl, aryl, heteroaryl, alkoxy, haloalkyl, oxo, and hydroxyl; "substituted aryl" refers to an aryl group having one or more substituents, including haloalkyl, alkyl, alkyl, alkyl, aryl, heteroaryl, alkoxy, haloalkyl, oxo, and hydroxyl.Alkyl, amino, haloalkyl, cycloalkyl, heterocyclic, heteroaryl, alkoxy, and cyano; "substituted heteroaryl" refers to a heteroaryl group having one or more substituents, including halogroup, amino, alkyl, haloalkyl, cycloalkyl, aryl, heterocyclic, heteroaryl, alkoxy, and cyano, and "substituted sulfonyl" refers to the group -S(O)2R, wherein R is substituted by one or more substituents, including alkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl. In other embodiments, the one or more substituents may be further substituted by halogroup, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclic, aryl, or heteroaryl, each of which is substituted. In other embodiments, the substituents may be further substituted by halogroup, alkyl, haloalkyl, alkoxy, hydroxyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, each of which is unsubstituted.

[0047] In some embodiments, the substituted cycloalkyl, substituted heterocyclic, substituted aryl, and / or substituted heteroaryl comprise cycloalkyl, heterocyclic, aryl, and / or heteroaryl having substituents on the ring atom, which are attached to the remainder of the compound. For example, in the following portion, the cyclopropyl group is substituted with a methyl group: .

[0048] The disclosure described illustratively herein may be practiced appropriately in the absence of any one or more elements or one or more limitations not specifically disclosed herein. Thus, terms such as “comprising,” “including,” “containing,” etc., should be understood broadly and without limitation. Furthermore, the terms and expressions used herein have been used as descriptive terms and not as limiting terms, and are not intended to exclude any equivalents or portions thereof of the features shown and described, but it should be recognized that various modifications are possible within the scope of the claimed disclosure.

[0049] The compounds of this disclosure may be in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to a salt prepared from a pharmaceutically acceptable non-toxic base or acid (including inorganic bases or inorganic acids and organic bases or organic acids). Where the compounds of this disclosure contain one or more acidic or basic groups, this disclosure also includes their corresponding pharmaceutically or toxicologically acceptable salts or pharmaceutically available salts. Thus, compounds of this disclosure containing acidic groups may be present on these groups and may be used according to this disclosure as, for example, alkali metal salts, alkaline earth metal salts, or ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts, or salts having ammonia or organic amines (e.g., ethylamine, ethanolamine, triethanolamine), amino acids, or other bases known to those skilled in the art. Compounds of this disclosure containing one or more basic groups (i.e., protonable groups) may be present in the form of their addition salts with inorganic or organic acids and may be used according to this disclosure.Examples of acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, neopentanoic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, aminosulfonic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to those skilled in the art.

[0050] If the compounds of this disclosure contain both acidic and basic groups in the molecule, this disclosure also includes, in addition to the salt forms mentioned, internal salts or betaine (zwitterions). The corresponding salts can be obtained by conventional methods known to those skilled in the art, for example, by contacting them with organic or inorganic acids or bases in a solvent or dispersant, or by anion or cation exchange with other salts.

[0051] This disclosure also includes all salts of the compounds disclosed herein, which are not directly applicable to pharmaceuticals due to low physiological compatibility, but may be used, for example, as intermediates in chemical reactions or for the preparation of pharmaceutically acceptable salts. Acids and bases that can be used to react with the compounds below to form pharmaceutically acceptable salts (acid addition salts or base addition salts, respectively) are known to those skilled in the art. Similarly, methods for preparing pharmaceutically acceptable salts from the compounds below (after disclosure) are known to those skilled in the art and disclosed, for example, in Berge et al., Journal of Pharmaceutical Science, January 1977, Vol. 66, No. 1, and other sources.

[0052] Furthermore, the compounds disclosed herein are susceptible to tautomerism. Where tautomerism (e.g., keto-enol tautomerism) of the compounds or their prodrugs is possible, individual forms (e.g., keto and enol forms) and mixtures thereof in any ratio are within the scope of this disclosure. This also applies to stereoisomers, such as enantiomers, cis / trans isomers, diastereomers, conformational isomers, etc.

[0053] The term "protecting group" refers to a part of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. Chemical protecting groups and protecting / deprotecting strategies are well known in the art (see, for example, Protective Groups in Organic Chemistry, Theodora W. Greene, John Wiley & Sons, Inc., New York, 1991). Protecting groups are often used to mask the reactivity of certain functional groups to contribute to the efficiency of desired chemical reactions, such as the orderly and planned formation and breaking of chemical bonds. The term "deprotecting" refers to the removal of a protecting group.

[0054] Those skilled in the art will understand that when the list of alternative substituents includes members that cannot be used to substitute for a particular group due to their valence requirements or other reasons, the list is intended to be interpreted by those skilled in the art as including only those members suitable for substituting for a particular group.

[0055] Furthermore, the compounds of this disclosure may exist in the form of solvates, such as those including water as a solvate, or pharmaceutically acceptable solvates, such as alcohols, particularly ethanol. A “solvent” is formed by the interaction of a solvent and a compound.

[0056] In some embodiments, optical isomers, racemates, or other mixtures thereof (e.g., non-racemate mixtures) of the compounds described herein or their pharmaceutically acceptable salts or mixtures thereof are provided. If desired, the isomers may be separated by methods well known in the art, such as by liquid chromatography. In these cases, a single enantiomer or diastereomer, i.e., the optically active form, may be obtained by asymmetric synthesis or by resolution. For example, resolution may be achieved by conventional methods, such as crystallization in the presence of a resolving agent, or chromatography using, for example, a chiral high-performance liquid chromatography (HPLC) column.

[0057] A “stereoisomer” is a compound consisting of identical atoms bonded by the same bonds but having different three-dimensional structures that are not interchangeable. This disclosure contemplates various stereoisomers and mixtures thereof, and includes “enantiomers”, which are two stereoisomers whose molecules are non-overlapping mirror images of each other. A “diastereomer” is a stereoisomer having at least two asymmetric atoms but not being a mirror image of each other. Unless otherwise specified, this specification is intended to include individual stereoisomers as well as mixtures thereof. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see, for example, Chapter 4 of Advanced Organic Chemistry, 4th Edition, J. March, John Wiley and Sons, New York, 1992).

[0058] In some embodiments, the compounds disclosed herein and their pharmaceutically acceptable salts may include asymmetric centers and thus may produce enantiomers, diastereomers, and other stereoisomers that may be defined by absolute stereochemistry as (R)- or (S)- or for amino acids as (D)- or (L). Some implementations include all such possible isomers as well as their racemic, non-racemic, and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L) isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques such as chromatography and fractional crystallization. Conventional techniques for preparing / separating individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of racemic compounds (or racemic compounds of salts or derivatives) using, for example, chiral high-performance liquid chromatography (HPLC). When the compounds described herein...When containing an alkene double bond or other geometrically asymmetric center, and unless otherwise stated, the compound is intended to include both the E geometric isomer and the Z geometric isomer. Similarly, it is also intended to include all tautomer forms. When a compound is expressed in its chiral form as described on page 9 / 60 of the specification, 16 CN 122206672 A, it should be understood that the embodiment covers, but is not limited to, a specific diastereomeric or enantiomer-enriched form. When chirality is not specified but is present, it should be understood that the embodiment relates to a specific diastereomeric or enantiomer-enriched form; or a racemic or non-racemic mixture of such compounds. As used herein, a “non-racemic mixture” is a mixture of stereoisomers in a ratio not of 1:1.

[0059] Compositions provided herein that include the compounds described herein or pharmaceutically acceptable salts, isomers, or mixtures thereof may include racemic mixtures or mixtures containing an enantiomer in excess of one enantiomer or a single diastereomeric or diastereomeric mixture. All such isomers of these compounds are explicitly included herein as if each and every isomer were specifically and individually listed.

[0060] Any formula or structure given herein is also intended to represent the unlabeled form of the compound as well as the isotopically labeled form. Isotopically labeled compounds have the structure described by the formula given herein, except that one or more atoms are replaced by atoms having a selected atomic mass or mass number. Examples of isotopes that may be incorporated into the compounds of this disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as, but not limited to, 2H (deuterium, D), 3H (tritium), 11C, 13C, 14C, 15N, 18F, 31P, 32P, 35S, 36Cl, and 125I. Various isotopically labeled compounds of this disclosure, for example in which radioactive isotopes such as 3H, 13C, and 14C are incorporated. Such isotopically labeled compounds can be used in metabolic studies, reaction kinetic studies, detection or imaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), including the determination of tissue distribution of drugs or substrates, or for radiotherapy of patients. The isotopically labeled compounds and their prodrugs of this disclosure can generally be prepared by replacing non-isotopically labeled reagents with readily available isotopically labeled reagents in the formulations or procedures disclosed in the examples and formulations described below.

[0061] This disclosure also includes “deuterium analogues” of the compounds disclosed herein, wherein 1 to n hydrogen atoms attached to a carbon atom are replaced with deuterium, where n is the number of hydrogen atoms in the molecule. Such compounds can exhibit increased resistance to metabolism and are therefore used to extend the half-life of any compound of formula (I) when administered to mammals (e.g., humans). See, for example, Foster, “Deuterium Isotope Effects in Studies of Drugs”."Metabolism", Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by methods well known in the art, for example by using starting materials in which one or more hydrogen atoms have been replaced by deuterium.

[0062] The deuterium-labeled or substituted therapeutic compounds of this disclosure may have beneficial DMPK (drug metabolism and pharmacokinetics) properties, which involve distribution, metabolism, and excretion (ADME). Substitution with a heavier isotope (such as deuterium) can provide certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life, reduced dose requirement, and / or improved therapeutic index. 18F-labeled compounds can be used in PET or SPECT studies.

[0063] The concentration of such heavier isotopes (particularly deuterium) can be defined by an isotope enrichment factor. In the compounds of this disclosure, any atom not specifically designated as a particular isotope means any stable isotope representing that atom. Unless otherwise stated, when a position is specifically designated as “H” or “hydrogen,” that position is understood to be hydrogen having its naturally abundant isotopic composition. Therefore, in the compounds of this disclosure, any atom specifically designated as deuterium (D) means representing deuterium.

[0064] Furthermore, this disclosure provides pharmaceutical compositions comprising, as an active ingredient, a compound of this disclosure, or a prodrug compound thereof, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

[0065] "Pharmaceutical composition" means one or more active ingredients, one or more inert ingredients constituting a carrier, and any product obtained directly or indirectly from the combination, complexation or aggregation of any two or more ingredients, or from the dissociation of one or more ingredients, or from other types of reactions or interactions of one or more ingredients. Therefore, the pharmaceutical compositions of this disclosure may cover any composition prepared by mixing at least one compound of this disclosure with a pharmaceutically acceptable carrier. Specification 10 / 60 pages 17 CN 122206672 A

[0066] As used herein, "pharmaceutically acceptable carrier" includes excipients or reagents that are harmless to the disclosed compound or its use, such as solvents, diluents, dispersion media, coatings, antimicrobial and antifungal agents, isotonic and absorption delay agents, etc. Compositions for preparing pharmaceutically active substances using such carriers and reagents are well known in the art (see, for example, "Remington's Pharmaceutical Sciences", Mace Publishing Co., Philadelphia, PA, 17th edition (1985); and Modern Pharmaceutics, Marcel Dekker, Inc., 3rd edition (edited by GSBanker and CTRhodes).

[0067] "Treatment" is a method used to achieve a beneficial or desired outcome, including clinical outcomes. A beneficial or desired clinical outcome includes one or more of the following: a) suppressing a disease or condition (e.g., reducing one or more symptoms caused by the disease or condition, and / or reducing the severity of the disease or condition); b) slowing or halting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and / or preventing or delaying its spread (e.g., metastasis of the disease or condition); and / or c) alleviating the disease, i.e., leading to the resolution of clinical symptoms (e.g., improving the disease state, providing partial or overall relief from the disease or condition, enhancing the effect of another medication, delaying the progression of the disease, increasing quality of life, and / or prolonging survival). In some embodiments, the term “treatment” means administering a compound or pharmaceutically acceptable salt of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) for the purpose of: (i) delaying the onset of a disease, i.e., preventing or delaying the development of clinical symptoms of the disease; (ii) suppressing the disease, i.e., preventing the development of clinical symptoms; and / or (iii) alleviating the disease, i.e. causing the reduction of clinical symptoms or their severity.

[0068] “Prevention” means any treatment of a disease or condition that prevents the development of clinical symptoms of the disease or condition. In some embodiments, the compound may be administered to subjects (including humans) who are at risk or have a family history of the disease or condition.

[0069] “Subject” means an animal, such as a mammal (including a human), which has been or will be the subject of treatment, observation, or experimentation. The methods described herein can be used for human therapeutic and / or veterinary applications. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.

[0070] The term "therapeutic effective amount" or "effective amount" refers to an amount sufficient to achieve a therapeutic effect when administered to a subject, providing a therapeutic benefit such as improvement of symptoms or slowing disease progression. For example, a therapeutic effective amount may be an amount sufficient to alleviate symptoms of a disease or condition that responds to a herpesvirus helicase-initiator inhibitor. Therapeutic effective amounts may vary depending on the subject, the disease or condition being treated, the subject's weight and age, the severity of the disease or condition, and the route of administration, which can be readily determined by those skilled in the art.

[0071] In one embodiment, this disclosure provides a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1 is, or; Specification 11 / 60 pages 18 CN 122206672 AR2a, R2b, and R2c are each independently H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, -CN, C1-6 haloalkoxy, or -SCF3; R3a and R3b are each independently H, halogen, C1-6 alkyl, or C1-6 haloalkyl; Xa and Xb are each independently O or CR7aR7b; each R7a is independently H, C1-6 alkyl, or C1-6 haloalkyl; each R7b is independently H, C1-6 alkyl, or C1-6 haloalkyl; R4a, R4b, and R4c are each independently H, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, -CN, -SCF3, or optionally a C3-6 cycloalkyl substituted with Z4; R5 is a C6-10 aryl or heteroaryl group; wherein the aryl or heteroaryl group of R5 is optionally substituted by one to three Z5 groups that are identical or different; the heteroaryl group of R5 is a 5- to 10-membered heteroaryl group having one to three heteroatoms that are each independently N, O or S; R6 is H, C1-6 alkyl, C1-6 haloalkyl, C2-8 alkoxyalkyl or C3-6 cycloalkyl, wherein the cycloalkyl group of R6 is optionally substituted by one to three Z6 groups; R8 is NHR9 or NR9R10; each R9, R10 and R12 is independently a C1-6 alkyl, C1-6 haloalkyl, -COR9a or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R9, R10 or R12 is optionally substituted by one to three groups independently selected from -OR12a and -SR12a; R11 is H, C1-6 alkyl, C1-6 haloalkyl, -COR9a, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R11 is optionally substituted with one to three groups, each independently of -OR12a or -SR12a; each R13 and R14 is independently H or C1-6 alkyl; R15 is C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R15 is optionally substituted with one to three groups, each independently of -OR12a or -SR12a; each R9a and R12a is independently C1-6 alkyl; and each Z4, Z5, and Z6 is independently halogen, -CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C1-6 haloalkoxy; provided that when R11 is H, R12 is not -CH3.

[0072] In some embodiments, the compound of formula (I) is compound (Ia) of formula (Ia) or a pharmaceutically acceptable salt thereof.

[0073] In some embodiments, the compound of formula (I) is compound (II) of formula (II) or a pharmaceutically acceptable salt thereof. Specification 12 / 60 pages 19 CN 122206672 A

[0074] In some embodiments, the compound of formula (I) is compound (IIa) of formula (IIa) or a pharmaceutically acceptable salt thereof.

[0075] In some embodiments, the compound of formula (I) is compound (III) of formula (III) or a pharmaceutically acceptable salt thereof.

[0076] In some embodiments, the compound of formula (I) is compound (IIIa) of formula (IIIa) or a pharmaceutically acceptable salt thereof.

[0077] In some embodiments, the compound of formula (I) is compound (IIIb) of formula (IIIb) or a pharmaceutically acceptable salt thereof.

[0078] In some embodiments, the compound of formula (I) is compound (IIIc) of formula (IIIc) or a pharmaceutically acceptable salt thereof.

[0079] In some embodiments, the compound of formula (I) is compound (IIId) of formula (IIId) or a pharmaceutically acceptable salt thereof.

[0080] In some embodiments, the compound of formula (I) is compound (IIIe) of formula (IIIe) or a pharmaceutically acceptable salt thereof.

[0081] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), or (IIIc), or a pharmaceutically acceptable salt thereof, is a compound in which R2a is H.

[0082] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), or (IIIc), or a pharmaceutically acceptable salt thereof, is a compound in which R2b is a halogen. In some embodiments, R2b is F.

[0083] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), or (IIIc), or a pharmaceutically acceptable salt thereof, is a compound in which R2c is H.

[0084] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), or (IIIb), or a pharmaceutically acceptable salt thereof, is a compound in which R3a is H.

[0085] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), or (IIIb), or a pharmaceutically acceptable salt thereof, is a compound in which R3b is H.

[0086] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), or (IIIc), or a pharmaceutically acceptable salt thereof, is a compound in which R4a is H.

[0087] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), or (IIIc) is a compound in which R3a is H.The compound or a pharmaceutically acceptable salt thereof is a compound in which R4b is H.

[0088] In some embodiments, the compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), or (IIIc) or a pharmaceutically acceptable salt thereof is a compound in which R4c is H.

[0089] In some embodiments, the compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), or (IIId) or a pharmaceutically acceptable salt thereof is a compound in which R5 is a heteroaryl; wherein the heteroaryl group of R5 can optionally be substituted by one to three Z5 groups that can be the same or different.

[0090] In some embodiments, the compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), or (IIId) or a pharmaceutically acceptable salt thereof is a compound in which R5 is a pyridyl group that can optionally be substituted by one to three Z5 groups that can be the same or different.

[0091] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), or (IIId), or a pharmaceutically acceptable salt thereof, is a compound in which R5 is pyridyl.

[0092] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is a compound in which R6 is H, a C1-6 alkyl, or a C1-6 haloalkyl. In some embodiments, R6 is H. In some embodiments, R6 is -CH3. Specification 14 / 60 pages 21 CN 122206672 A

[0093] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof is such a compound, wherein R1 is

[0094] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof is such a compound, wherein R1 is; R8 is NHR9 or NR9R10; each R9 and R10 is independently C1-6 alkyl, C1-6 haloalkyl, -COR9a, or C3-6 cycloalkyl; the C1-6 alkyl of R9 or R10 is optionally substituted with -OR12a; andEach R9a and R12a is independently a C1-6 alkyl group.

[0095] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is a compound in which R1 is; R8 is NHR9; R9 is a C1-6 alkyl group or -COR9a; and R9a is a C1-6 alkyl group.

[0096] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is a compound in which R1 is or

[0097] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is a compound in which R1 is

[0098] In some embodiments, a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is a compound in which R1 is

[0098] ; R11 is H; R12 is -CH2OR12a, C2-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl; the alkyl or cycloalkyl of R12 is optionally substituted with -OR12a; and R12a is C1-6 alkyl.

[0099] In some embodiments, compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, are compounds in which R1 is; R11 is H; R12 is C2-6 alkyl or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R12 is optionally substituted with -OR12a; and R12a is C1-6 alkyl.

[0100] In some embodiments, compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, are compounds in which R1 is, , or.

[0101] In some embodiments, formulas (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc)The compounds of formula (IIId) or (IIIe) or their pharmaceutically acceptable salts are compounds in which R1 is; R11 is a C1-6 alkyl; R12 is a C1-6 alkyl, C1-6 haloalkyl, or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R12 is optionally substituted with -OR12a; and R12a is a C1-6 alkyl.

[0102] In some embodiments, the compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId) or (IIIe) or their pharmaceutically acceptable salts are compounds in which R1 is; R11 is a C1-6 alkyl; R12 is a C1-6 alkyl or C3-6 cycloalkyl; the alkyl or cycloalkyl group of R12 is optionally substituted with -OR12a; and R12a is a C1-6 alkyl.

[0103] In some embodiments, compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, are compounds in which R1 is

[0104] In some embodiments, this disclosure provides compounds having the structures of the compounds in Table 1, or pharmaceutically acceptable salts thereof. In some embodiments, this disclosure provides compounds having the structures of the compounds in Table 1, or pharmaceutically acceptable salts thereof, stereoisomers, or mixtures of stereoisomers thereof.

[0105] Table 1. Some Compound Specifications 16 / 60 pages 23 CN 122206672 A Specifications 17 / 60 pages 24 CN 122206672 A Specifications 18 / 60 pages 25 CN 122206672 A Specifications 19 / 60 pages 26 CN 122206672 A Specifications 20 / 60 pages 27 CN 122206672 A In some embodiments, this disclosure provides racemic mixtures comprising compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or pharmaceutically acceptable salts thereof. In some embodiments, this disclosure provides racemic mixtures comprising compounds disclosed herein or pharmaceutically acceptable salts thereof. In some embodiments, this disclosure provides non-racemic mixtures comprising compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or pharmaceutically acceptable salts thereof. In some embodiments, this disclosure provides non-racemic mixtures comprising the compounds disclosed herein or pharmaceutically acceptable salts thereof.

[0106] Those skilled in the art will recognize that each embodiment of the groups disclosed herein (e.g., R1) may be combined with any other embodiment of each of the remaining groups (e.g., R2a, R2b, R2c, R3a, R3b, etc.) to produce a complete compound of formula (I) or any of the formulas described herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or tautomer thereof, each of which is considered to be within the scope of this disclosure.

[0107] Compositions and Kits The compounds provided herein or pharmaceutically acceptable salts thereof are generally administered in the form of pharmaceutical compositions. Therefore, pharmaceutical compositions are also provided herein that comprise one or more of the compounds provided herein or pharmaceutically acceptable salts, isomers, or mixtures thereof, and one or more pharmaceutically acceptable solvents selected from carriers, adjuvants, and excipients. The compounds provided herein or pharmaceutically acceptable salts thereof may be the sole active ingredient or one of the active ingredients of a pharmaceutical composition. Suitable pharmaceutically acceptable solvents may include, for example, inert solid diluents and fillers, diluents including sterile aqueous solutions and various organic solvents, permeation enhancers, solubilizers, and adjuvants. Such compositions are prepared in a manner well known in the pharmaceutical field. See, for example, Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa., 17th edition, (1985); and Modern Pharmaceutics, Marcel Dekker, Inc., 3rd edition (edited by GSBanker and CTRhodes).

[0108] In some embodiments, pharmaceutical compositions are provided herein comprising a compound provided herein (i.e., a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe)) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

[0109] In some embodiments, the pharmaceutical compositions provided herein further comprise one or more (i.e., one, two, three, four; one or two; one to three; or one to four) additional therapeutic agents or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical compositions further comprise a therapeutically effective amount of one or more (i.e., one, two, three, four; one or two; one to three; or one to four) additional therapeutic agents or pharmaceutically acceptable salts thereof. In some embodimentsIn this regimen, one or more therapeutic agents are selected from complement receptor 2 antagonists; Duffy antigen chemokine receptor modulators; envelope glycoprotein GP350 modulators; glucocorticoid receptor agonists; helicase inhibitors; helicase-primase inhibitors; HIV gp160 protein inhibitors; HIV gp41 protein inhibitors; HIV-1 reverse transcriptase inhibitors; HLA class I antigen A-2α modulators; HLA class I antigen A-24α modulators; human cytomegalovirus glycoprotein B modulators; human cytomegalovirus glycoprotein H modulators; human cytomegalovirus glycoprotein inhibitors; human cytomegalovirus glycoprotein L modulators; immunoglobulin G agonists; interferon α2 ligands; interferon γ receptor antagonists; latent membrane protein 1 modulators; latent membrane protein 2 modulators; latent membrane protein 2 stimulators; Progesterone receptor agonists; BARF1 secretory protein regulators; UL97 serine-threonine protein kinase regulators; CD8 stimulators on T cell surface glycoproteins; thymidine kinase inhibitors; ICP4 trans-acting transcription protein regulators; transferase inhibitors; unspecified gene inhibitors; adenosine homocysteine ​​kinase inhibitors; basigin inhibitors; basigin regulators; CCR5 chemokine regulators; CD4 agonists; CD4 regulators; CD89 agonists; CMV 65kDa matrix phosphoprotein regulators; CRISPR-associated endonuclease Cas9 regulators; cyclin-dependent kinase inhibitors; cyclin-dependent kinase inhibitors; cyclin-dependent kinase-9 inhibitors; DNA polymerase inhibitors; DNA primase inhibitors; endonuclease regulators; Epstein-Barr nuclear antigen 1 inhibitors; Epstein-Barr nuclear antigen 1 regulators; Epstein-Barr nuclear antigen 1 stimulators; fatty acid synthase inhibitors; herpesvirus envelope glycoprotein B stimulators; herpesvirus envelope glycoprotein D inhibitors. Herpesvirus envelope glycoprotein D modulator; HIV gp120 protein inhibitor; HLA class I antigen A-11α modulator; Hsp 90 inhibitor; human cytomegalovirus glycoprotein B inhibitor; human cytomegalovirus glycoprotein B modulator; human cytomegalovirus glycoprotein inhibitor; hyaluronidase inhibitor; immunoglobulin agonist; interferon α1 ligand; interferon α2 ligand; interferon α ligand inhibitor; interferon α ligand modulator; interferon β ligand; large terminal enzyme protein inhibitor; LAT gene inhibitor; NAD-dependent deacetylase sirtuin modulator; nicotinic acetylcholine receptor antagonist; NKG2D ligand modulator; nucleotide transferase inhibitor; protein Jumonji inhibitor; ribonuclease stimulator; serine-threonine protein kinase UL97 inhibitor; synaptic fusion protein-5 inhibitor; TAT protein modulator; T cell surface glycoprotein CD8 stimulator; TLR-4 agonist; and viruses.Ribonucleotide reductase inhibitors. In some embodiments, one or more therapeutic agents are selected from famciclovir, acyclovir, and valacyclovir.

[0110] In some embodiments, pharmaceutical compositions are provided herein comprising a therapeutically effective amount of the compound provided herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Specification 22 / 60 pages 29 CN 122206672 A

[0111] The pharmaceutical composition may be administered in single or multiple doses. The pharmaceutical composition may be administered by various methods, including, for example, rectal, buccal, intranasal, and transdermal routes. In some embodiments, the pharmaceutical composition may be administered by intra-arterial injection, intravenous, intraperitoneal, parenteral, intramuscular, subcutaneous, oral, topical, or as an inhaler.

[0112] One method of administration is parenteral, for example by injection. The pharmaceutical compositions described herein may be incorporated into, for example, aqueous or oil suspensions or emulsions for administration by injection, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or sterile aqueous solutions and similar pharmaceutical solvents. In some embodiments, the compounds disclosed herein or their pharmaceutically acceptable salts and pharmaceutical compositions are administered by subcutaneous injection.

[0113] The pharmaceutical compositions of this disclosure may be in the form of sterile injectable formulations, such as sterile injectable aqueous or oil suspensions. Such suspensions may be formulated using suitable dispersants or wetting agents and suspending agents already mentioned herein, according to known techniques. Sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic, parenteral-acceptable diluents or solvents (such as solutions in 1,3-butanediol), or prepared as lyophilized powders. Acceptable solvents and media that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, non-volatile oils are generally used as solvents or suspension media. For this purpose, any mild, non-volatile oil, including synthetic monoglycerides or diglycerides, can be used. Additionally, fatty acids such as oleic acid can also be used in the preparation of injectable formulations.

[0114] In some embodiments, the sterile injectable formulations disclosed herein can also be sterile injectable solutions or suspensions (such as solutions in 1,3-butanediol) prepared from reconstituted lyophilized powders in a non-toxic, parenteral acceptable diluent or solvent. Acceptable solvents and media that can be used are water, Ringer's solution, and isotonic sodium chloride solution. Furthermore, sterile, non-volatile oils are generally used as solvents or suspension media. For this purpose, any mild, non-volatile oil, including synthetic monoglycerides or diglycerides, can be used. Additionally, fatty acids such as oleic acid can also be used in the preparation of injectable formulations.

[0115] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injectable solutions that may contain antioxidants, buffers, antibacterial agents, and solutes to make the formulation isotonic with the blood of the intended recipient; and may include suspending agents and thickeners.Aqueous and non-aqueous sterile suspensions. In some embodiments, the suspension is a microsuspension. In some embodiments, the suspension is a nanosuspension.

[0116] In some embodiments, formulations suitable for parenteral administration (e.g., intramuscular (IM) and subcutaneous (SC) administration) will contain one or more excipients. The excipients should be compatible with the other components of the formulation and physiologically harmless to the recipient. Examples of suitable excipients are well known to those skilled in the art of parenteral formulations and can be found, for example, in the Handbook of Pharmaceutical Excipients (edited by Rowe, Sheskey, and Quinn), 6th edition, 2009. Examples of solubilizing excipients in parenteral formulations (e.g., SC or IM formulations) include, but are not limited to, polysorbates (e.g., polysorbate 20 or 80) and poloxamer (e.g., poloxamer 338, 188, or 207). In some embodiments, compounds disclosed herein or pharmaceutically acceptable salts thereof and pharmaceutical compositions are administered together with the implant.

[0117] Oral administration may be another route for administering the compounds provided herein or pharmaceutically acceptable salts thereof. Administration may be via, for example, capsules or enteric-coated tablets. In preparing pharmaceutical compositions comprising at least one compound provided herein or a pharmaceutically acceptable salt, isomer, or mixture thereof, the active ingredient (such as the compounds provided herein) is typically diluted with an excipient and / or encapsulated in such a carrier, which may be in the form of capsules, sachets, paper, or other containers. When the excipient is used as a diluent, it may be in the form of a solid, semi-solid, or liquid material, which acts as a solvent, carrier, or medium for the active ingredient. Thus, pharmaceutical compositions may be in the form of tablets, pills, powders, lozenges, capsules, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft gelatin capsules and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.

[0118] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum, calcium phosphate, alginate, tragacanth gum, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methylcellulose, or any combination thereof. Pharmaceutical compositions may additionally include lubricants such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives such as methyl benzoate and propylparaben; sweeteners; and flavoring agents; or any combination thereof.

[0119] Pharmaceutical compositions comprising at least one compound described herein or a pharmaceutically acceptable salt, isomer, or mixture thereof can be formulated to provide an active ingredient (such as...) upon administration to a subject using procedures known in the art.Rapid, sustained, or delayed release of the compounds provided herein. Controlled-release drug delivery systems for oral administration include osmotic pump systems and dissolution systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled-release systems are given in U.S. Patent Nos. 3,845,770, 4,326,525, 4,902,514, and 5,616,345. Another formulation used in the methods of this disclosure employs a transdermal delivery device (“patch”). Such transdermal patches can be used to provide a controlled amount of the compounds provided herein for continuous or discontinuous infusion. The construction and use of transdermal patches for drug delivery are well known in the art. See, for example, U.S. Patent Nos. 5,023,252, 4,992,445, and 5,001,139. ​​Such patches can be constructed for continuous, pulsatile, or on-demand delivery of drugs.

[0120] To prepare solid compositions (such as tablets), a major active ingredient may be mixed with a pharmaceutical excipient to form a solid preformed composition containing a homogeneous mixture of the compounds described herein or their pharmaceutically acceptable salts, isomers, or mixtures thereof. When these preformed compositions are referred to as homogeneous, the active ingredient is uniformly dispersed throughout the composition, making it easy to subdivide the composition into equivalent unit dosage forms, such as tablets, pills, and capsules.

[0121] Tablets or pills of the compounds provided herein or their pharmaceutically acceptable salts may be coated or otherwise compounded to provide a dosage form with the advantage of prolonged action or protection against the acidic conditions of the stomach. For example, tablets or pills may contain an inner dose component and an outer dose component, the latter being in the form of a coating over the former. These two components may be separated by an enteric coating layer, which is used to resist disintegration in the stomach and allow the inner component to enter the duodenum intact or to delay release. A variety of materials may be used for such enteric coatings or coatings, including a variety of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.

[0122] Pharmaceutical compositions for inhalation or inhalation may include solutions and suspensions or mixtures thereof in pharmaceutically acceptable aqueous or organic solvents, as well as powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In some embodiments, the composition is administered via oral or nasal inhalation to achieve a local or systemic effect. In other embodiments, the composition may be nebulized in a pharmaceutically acceptable solvent using an inert gas. The nebulized solution may be inhaled directly from a nebulizer, or the nebulizer may be attached to a face mask tent or intermittent positive pressure ventilation machine. Solution, suspension, or powder compositions may be administered orally or nasally from a device that delivers the formulation in a suitable manner.

[0123] In one embodiment, a kit is provided herein containing the compounds provided herein (i.e., formula...).(I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) compounds thereof) or pharmaceutically acceptable salts, stereoisomers, prodrugs, or solvates thereof, and suitable packaging. In some embodiments, the kit also includes instructions for use. In some embodiments, the kit contains the compounds provided herein (i.e., compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe)) or pharmaceutically acceptable salts, stereoisomers, prodrugs, or solvates thereof, and labeling and / or instructions for using the compound to treat the indications (including diseases or conditions) described herein.

[0124] In some embodiments, the kit also includes one or more (i.e., one, two, three, four; one or two; one to three; or one to four) additional therapeutic agents or pharmaceutically acceptable salts thereof.

[0125] In one embodiment, an article of manufacture is provided herein containing, in a suitable container, the compound described herein (page 24 / 60, 31 CN 122206672 A) or a pharmaceutically acceptable salt, isomer, or mixture thereof. In some embodiments, the container may be a vial, wide-mouth bottle, ampoule, pre-filled syringe, or intravenous bag.

[0126] Methods The methods provided herein can be applied to cell populations in vivo or in vitro. “In vivo” means within a living individual, such as in an animal or human. In this context, the methods provided herein can be used for the treatment of an individual. “In vitro” means outside a living individual. Examples of in vitro cell populations include in vitro cell cultures and biological samples, including fluid or tissue samples obtained from an individual. Such samples can be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies. In this context, this disclosure can be used for a variety of purposes, including therapeutic and experimental purposes. For example, this disclosure can be used in vitro to determine the optimal administration schedule and / or dosage of the compounds disclosed herein for a given cell type, individual, and other parameters. Information gathered from such uses can be used for experimental purposes or clinically for developing in vivo treatment regimens. Other in vitro uses of this disclosure that may be suitable are described below or will become apparent to those skilled in the art. The selected compounds may be further characterized to examine safety or tolerability doses in human or non-human subjects. Such properties can be examined using methods generally known to those skilled in the art.

[0127] In one embodiment, this disclosure provides a method of treating or preventing herpesvirus infection in a patient in need, the method comprising administering to the patient a therapeutically effective amount of the compound provided herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition provided herein.

[0128] In some embodiments, the methods provided herein further include administering a therapeutically effective amount of one, two, three, or four additional therapeutic agents or pharmaceutically acceptable salts thereof.

[0129] This disclosure further relates to the use of the compounds disclosed herein for treating and / or preventing diseases and / or conditions by inhibiting the helicase priming enzyme of herpesviruses by said compounds. Furthermore, this disclosure relates to the use of said compounds for preparing medicaments for treating and / or preventing herpesvirus-related diseases and / or conditions by inhibiting the helicase priming enzyme of herpesviruses by said compounds. In some embodiments, herpesvirus-related diseases or conditions are relieved by inhibiting the herpesvirus helicase priming enzyme. In some embodiments, this disclosure relates to the use of the compounds disclosed herein for preparing medicaments for treating and / or preventing HSV-1 or HSV-2-related diseases and / or conditions by inhibiting the helicase priming enzyme by said compounds.

[0130] Medicaments as referred to herein can be prepared by conventional methods, including combinations of compounds according to this disclosure and pharmaceutically acceptable carriers.

[0131] In some embodiments, this document provides a method for inhibiting the helicase-initiating enzyme of herpesviruses, the method comprising administering to a patient in need (e.g., a patient suffering from a herpesvirus-related disease or condition) a therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof.

[0132] In some embodiments, this document provides a method for inhibiting the helicase priming enzyme of HSV-1 or HSV-2, the method comprising administering to a patient in need (e.g., a patient suffering from an HSV-1 or HSV-2 related disease or condition) a therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof. In some embodiments, this document provides a method for inhibiting the helicase priming enzyme of HSV-1 or HSV-2, the method comprising administering to a patient in need (e.g., a patient suffering from an HSV-1 or HSV-2 related disease or condition) a therapeutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof. (Description 25 / 60 pages 32 CN)122206672 A An acceptable salt, or a composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof.

[0133] In some embodiments, a method for reducing viral proliferation is provided herein, comprising contacting the virus with a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof, and inhibiting a helicase priming enzyme in the virus. In some embodiments, a method for reducing the proliferation of a herpesvirus is provided herein, comprising contacting the virus with a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof, and inhibiting a helicase priming enzyme in the virus. In some embodiments, a method for reducing the proliferation of HSV-1 or HSV-2 is provided herein, comprising contacting the virus with a compound disclosed herein or a pharmaceutically acceptable salt thereof, and inhibiting a helicase priming enzyme in the virus.

[0134] In some embodiments, this document provides a method for treating a disorder induced, aggravated, or accelerated by a herpesvirus, the method comprising administering to a patient a therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof, or administering to a patient in need a therapeutically effective amount of a composition comprising a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof. In some embodiments, this document provides a method for treating a disorder induced, aggravated, or accelerated by HSV-1 or HSV-2, the method comprising administering to a patient a therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof, or administering to a patient in need a therapeutically effective amount of a composition comprising a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof. In some embodiments, the disorder is genital herpes, cold sores, HSV keratitis, HSV encephalitis, or disseminated HSV. In some embodiments, the disorder is genital herpes.

[0135] In some embodiments, this document provides the use of compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, in the treatment of viral infections. In some embodiments, this document provides the use of compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, in the treatment of viral infections caused by herpesviruses. In some embodiments, this document provides the use of compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, in the treatment of viral infections caused by HSV-1 or HSV-2.

[0136] In some embodiments, the use of compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, for the preparation of medicaments for the prevention / treatment of viral infections. In some embodiments, the use of compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, for the preparation of medicaments for the prevention / treatment of viral infections caused by herpesviruses. In some embodiments, the use of compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, for the preparation of medicaments for the prevention / treatment of viral infections caused by HSV-1 or HSV-2, is provided herein.

[0137] In some embodiments, compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or pharmaceutically acceptable salts thereof are provided herein for use in a therapeutic manner. In some embodiments, compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or pharmaceutically acceptable salts thereof are provided herein for use in a method of treating viral infections caused by HSV-1 or HSV-2. Specification 26 / 60 pages 33 CN 122206672 A

[0138] ApplicationThe compounds disclosed herein, or pharmaceutically acceptable salts thereof (also referred to herein as active ingredients), may be administered via any route suitable for the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal, and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal, and epidural). It should be understood that preferred routes may vary depending on, for example, the recipient's condition. An advantage of some of the compounds disclosed herein, or pharmaceutically acceptable salts thereof, is that they are orally bioavailable and can be administered orally.

[0139] The compounds disclosed herein, or pharmaceutically acceptable salts thereof, may be administered according to an effective dosing regimen for a period of time or duration desired by the individual, such as at least about one day, at least about two days, at least about three days, at least about four days, at least about five days, at least about six days, at least about one week, at least about two weeks, at least about three weeks, at least about one month, at least about two months, at least about three months, at least about six months, or at least about twelve months or longer. In some embodiments, the compounds, or pharmaceutically acceptable salts thereof, are administered on a daily or intermittent schedule over the lifetime of the individual.

[0140] The specific dose level of the compounds disclosed herein or their pharmaceutically acceptable salts for any particular subject will depend on a variety of factors, including the activity of the specific compound used, the age, weight, general health condition, sex, diet, time of administration, route of administration and excretion rate, drug combination, and severity of the specific disease. For example, a dose may be expressed as milligrams of the compounds provided herein or their pharmaceutically acceptable salts per kilogram of subject weight (mg / kg). A dose between about 0.1 mg / kg and 150 mg / kg may be appropriate. In some embodiments, a dose between about 0.1 mg / kg and 100 mg / kg may be appropriate. In other embodiments, a dose between 0.5 mg / kg and 60 mg / kg may be appropriate. Normalization based on the subject's weight is particularly useful when adjusting doses among subjects with large differences in size (such as when using a drug in children and adults, or when converting an effective dose for a non-human subject, such as a dog, to a dose suitable for a human subject).

[0141] A dose may also be described as the total amount of the compounds described herein or their pharmaceutically acceptable salts administered at each dose. The dosage or frequency of administration of the compounds of this disclosure or pharmaceutically acceptable salts thereof may be adjusted during treatment based on the judgment of the administering physician.

[0142] The compounds of this disclosure or pharmaceutically acceptable salts thereof may be administered in therapeutically effective amounts to an individual (e.g., a human). In some embodiments, formulas (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), and (IIId) are used.Compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or their pharmaceutically acceptable salts may be administered once daily, weekly, monthly, every two months, every three months, or every six months. In some embodiments, compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or their pharmaceutically acceptable salts may be administered once daily. In some embodiments, compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or their pharmaceutically acceptable salts may be administered once weekly. In some embodiments, compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or their pharmaceutically acceptable salts may be administered once monthly. In some embodiments, the compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, are administered every two months. In some embodiments, the compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, are administered every three months. In some embodiments, the compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, are administered every six months.

[0143] The compounds provided herein or pharmaceutically acceptable salts thereof may be administered by any useful route and means, such as by oral or parenteral (e.g., intravenous) administration. Therapeutic effective amounts of the compound or its pharmaceutically acceptable salts, as per the product information (pages 27 / 60, 34, CN 122206672 A), may include from about 0.00001 mg / kg body weight / day to about 10 mg / kg body weight / day, such as from about 0.0001 mg / kg body weight / day to about 10 mg / kg body weight / day, or such as from about 0.001 mg / kg body weight / day to about 1 mg / kg body weight / day, or such as from about 0.01 mg / kg body weight / day to about 1 mg / kg body weight / day, or such as from about 0.05 mg / kg body weight / day to about 0.5 mg / kg body weight / day. In some embodiments, the therapeutic effective amounts of the compound or its pharmaceutically acceptable salts provided herein include from about 30 µg / day to about 300 µg / day.g / day, about 0.3 mg / day to about 30 mg / day, or about 30 mg / day to about 300 mg / day, or about 300 mg / day to about 1000 g / day.

[0144] The compounds of this disclosure or pharmaceutically acceptable salts thereof may be combined with one or more additional therapeutic agents at any dose (e.g., 1 mg to 1000 mg of the compound) of the compounds of this disclosure or pharmaceutically acceptable salts thereof. Therapeutic effective doses may include from about 0.1 mg / dose to about 1000 mg / dose, such as from about 50 mg / dose to about 500 mg / dose, or such as from about 100 mg / dose to about 400 mg / dose, or such as from about 150 mg / dose to about 350 mg / dose, or such as from about 200 mg / dose to about 300 mg / dose, or such as from about 0.01 mg / dose to about 1000 mg / dose, or such as from about 0.01 mg / dose to about 100 mg / dose, or such as from about 0.1 mg / dose to about 100 mg / dose, or such as from about 1 mg / dose to about 100 mg / dose, or such as from about 1 mg / dose to about 1000 mg / dose. Other therapeutically effective doses of compounds of formula (I), (IIa), (IIb), (IIc), (IId), (IIe), or (IIf) or their pharmaceutically acceptable salts are about 50 mg / dose, 100 mg / dose, 125 mg / dose, 150 mg / dose, 175 mg / dose, 200 mg / dose, 225 mg / dose, 250 mg / dose, 275 mg / dose, or 300 mg / dose. Other therapeutically effective doses of compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or their pharmaceutically acceptable salts, are about 300 mg / dose, 325 mg / dose, 350 mg / dose, 375 mg / dose, 400 mg / dose, 425 mg / dose, 450 mg / dose, 475 mg / dose, 500 mg / dose, 525 mg / dose, 550 mg / dose, 575 mg / dose, 600 mg / dose, 625 mg / dose, 650 mg / dose, 675 mg / dose, 700 mg / dose, 725 mg / dose, 750 mg / dose, 775 mg / dose, 800 mg / dose, 825 mg / dose, 850 mg / dose, 875 mg / dose. 900 mg / dose, 925 mg / dose, 950 mg / dose, 975 mg / dose, or about 1000 mg / dose.

[0145] In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof is about 1 mg to about 1000 mg.In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 900 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 800 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 700 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 600 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 500 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 400 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 300 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 200 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 100 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III ...The therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 1 mg to about 75 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 1 mg to about 50 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 1 mg to about 25 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 20 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 15 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 10 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof is about 1 mg to about 5 mg.

[0146] In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof is about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 275 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about850 mg, about 900 mg, about 950 mg, about 1000 mg, or about 1050 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 5 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 100 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 150 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 200 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 250 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 300 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 350 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 400 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 450 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 450 mg.A therapeutically effective amount of a compound of formula (IIId) or (IIIe) or a pharmaceutically acceptable salt thereof is about 500 mg. In some embodiments, a therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof is about 550 mg. In some embodiments, a therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof is about 600 mg. In some embodiments, a therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof is about 650 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 700 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 750 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 800 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 850 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 900 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 950 mg. In some embodiments, the therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 950 mg.A therapeutically effective amount of a compound of formula (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 1000 mg. In some embodiments, a therapeutically effective amount of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, is about 1050 mg. When administered orally, the total weekly dose to human subjects may be between about 1 mg / week and 1,000 mg / week, between about 10 mg / week and 500 mg / week, between about 50 mg / week and 300 mg / week, between about 75 mg / week and 200 mg / week, or between about 100 mg / week and 150 mg / week. In some embodiments, the total weekly dose administered as a single dose to a human subject may be about 100 mg / week, 200 mg / week, 300 mg / week, 400 mg / week, 500 mg / week, 600 mg / week, 700 mg / week, 800 mg / week, 900 mg / week, or 1000 mg / week. In some embodiments, for a human subject, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 100 mg. In some embodiments, for a human subject, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 150 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 200 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 250 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 300 mg. In some embodiments, for human subjects…For human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 350 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 400 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 450 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 500 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 600 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 700 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 800 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 900 mg. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 900 mg.The total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 1,000 mg.

[0147] When administered orally, the total monthly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) or a pharmaceutically acceptable salt thereof, for human subjects, may be between about 500 mg / month and 1,000 mg / month, between about 600 mg / month and 900 mg / month, or between about 700 mg / month and 800 mg / month. In some embodiments, for human subjects, the total weekly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 100 mg / week, 200 mg / week, 300 mg / week, 400 mg / week, 500 mg / week, 600 mg / week, 700 mg / week, 800 mg / week, 900 mg / week, or 1000 mg / week. In some embodiments, for human subjects, the total monthly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 500 mg. In some embodiments, the total monthly dose for human subjects administered as a single dose may be about 550 mg. In some embodiments, for human subjects, the total monthly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 600 mg. In some embodiments, for human subjects, the total monthly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 650 mg. In some embodiments, for human subjects, the total monthly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 700 mg. In some embodiments, for human subjects, the total monthly dose of a compound of formula (I), (Ia), (II), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 700 mg.The total monthly dose of compounds of formula (I), (Ia), (II), (IIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, administered as a single dose, may be about 750 mg. In some embodiments, for human subjects, the total monthly dose of compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, administered as a single dose, may be about 800 mg. In some embodiments, for human subjects, the total monthly dose of compounds of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or pharmaceutically acceptable salts thereof, administered as a single dose, may be about 850 mg. In some embodiments, for human subjects, the total monthly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 900 mg. In some embodiments, for human subjects, the total monthly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 950 mg. In some embodiments, for human subjects, the total monthly dose of a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), or a pharmaceutically acceptable salt thereof, administered as a single dose, may be about 1000 mg.

[0148] A single dose may be administered hourly, daily, weekly, or monthly. For example, a single dose may be administered every 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, or 16 hours, or every 24 hours. A single dose may also be administered every 1 day, 2 days, 3 days, 4 days, 5 days, or 6 days, or every 7 days. A single dose may also be administered once every 1 week, 2 weeks, or 3 weeks, or once every 4 weeks. In some embodiments, a single dose may be administered once weekly. A single dose may also be administered once monthly. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered once daily in the methods disclosed herein. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered twice daily in the methods disclosed herein.

[0149] In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered once daily in the method disclosed herein. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered once weekly in the method disclosed herein. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered once monthly in the method disclosed herein. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered once every two months in the method disclosed herein. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered once every three months in the method disclosed herein. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered once every six months in the method disclosed herein.

[0150] In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once weekly in a single dose of about 100 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once weekly in a single dose of about 150 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once weekly in a single dose of about 200 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once weekly in a single dose of about 250 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once weekly in a single dose of about 300 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once weekly in a single dose of about 350 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once weekly in a single dose of about 400 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once weekly in a single dose of about 450 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once weekly in a single dose of about 500 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once weekly in a single dose of about 600 mg.

[0151] In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once monthly in a single dose of about 500 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once monthly in a single dose of about 550 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once monthly in a single dose of about 600 mg. In some embodiments, the compound provided herein or a pharmaceutically acceptable salt thereof is administered orally once monthly in a single dose of about 650 mg. In some embodiments, the compound provided herein...The compound or a pharmaceutically acceptable salt thereof is administered orally once monthly in a single dose of about 700 mg. In some embodiments, the compound or a pharmaceutically acceptable salt thereof provided herein is administered orally once monthly in a single dose of about 750 mg. In some embodiments, the compound or a pharmaceutically acceptable salt thereof provided herein is administered orally once monthly in a single dose of about 800 mg. In some embodiments, the compound or a pharmaceutically acceptable salt thereof provided herein is administered orally once monthly in a single dose of about 850 mg. In some embodiments, the compound or a pharmaceutically acceptable salt thereof provided herein is administered orally once monthly in a single dose of about 900 mg. In some embodiments, the compound or a pharmaceutically acceptable salt thereof provided herein is administered orally once monthly in a single dose of about 950 mg. In some embodiments, the compound or a pharmaceutically acceptable salt thereof provided herein is administered orally once monthly in a single dose of about 1000 mg.

[0152] The frequency of administration of the compound or a pharmaceutically acceptable salt thereof disclosed herein will be determined by the needs of the individual patient and may be, for example, once daily, once weekly, once monthly, once every two months, once every three months, or once every six months. The duration necessary for continuous treatment of herpesvirus infections (including HSV-1 and HSV-2 infections) with the administration of the compound or a pharmaceutically acceptable salt thereof.

[0153] The administration may be intermittent, with the patient receiving a daily dose of the disclosed compound or a pharmaceutically acceptable salt thereof for a period of several days or more, followed by a period of several days or more without receiving a daily dose of the compound or a pharmaceutically acceptable salt thereof. For example, the patient may receive a dose of the compound or a pharmaceutically acceptable salt thereof every other day or three times a week. To reiterate, a patient may receive a daily dose of the compound or its pharmaceutically acceptable salt for a period of 1 to 14 days, followed by a period of 7 to 21 days without receiving a daily dose of the compound or its pharmaceutically acceptable salt, and then again for a subsequent period (e.g., 1 to 14 days) with a daily dose of the compound or its pharmaceutically acceptable salt. The alternating periods of administration of the compound or its pharmaceutically acceptable salt followed by non-administration may be repeated as needed for the patient's clinical treatment.

[0154] The compounds or their pharmaceutically acceptable salts, or the pharmaceutical compositions of this disclosure, may be administered once, twice, three times, or four times daily using any of the suitable methods described above. Furthermore, administration with the compound or its pharmaceutically acceptable salts...Treatment may continue for several days; for example, for a treatment cycle, treatment typically continues for at least 7, 14, or 28 days. Treatment cycles for herpesvirus infections (including HSV-1 and HSV-2 infections) are well known. In some embodiments, treatment cycles typically alternate with rest periods of about 1 to 28 days, typically about 7 days or about 14 days, between cycles. In other embodiments, treatment cycles may also be continuous.

[0155] The effective dose of the active ingredient used may vary depending on the specific compound used, the administration method, the condition being treated, and the severity of the condition being treated. Such doses can be readily determined by those skilled in the art.

[0156] Combinations In some embodiments, compounds of formulas (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or pharmaceutically acceptable salts thereof, are administered in combination with one or more adjunct therapeutic agents to treat or prevent the diseases or conditions disclosed herein. In some embodiments, the one or more adjunct therapeutic agents are one, two, three, or four adjunct therapeutic agents. In some embodiments, one or more adjuvant therapeutic agents are one adjuvant therapeutic agent.

[0157] In some embodiments, one or more adjuvant therapeutic agents are two adjuvant therapeutic agents. In some embodiments, one or more adjuvant therapeutic agents are three adjuvant therapeutic agents. In some embodiments, one or more adjuvant therapeutic agents are four adjuvant therapeutic agents.

[0158] In some embodiments, the pharmaceutical compositions provided herein have a compound of formula (I), (Ia), (II), (IIa), (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe) provided herein, or a pharmaceutically acceptable salt thereof, and one or more adjuvant therapeutic agents. In some embodiments, one or more adjuvant therapeutic agents are one, two, three, or four adjuvant therapeutic agents. In some embodiments, one or more adjuvant therapeutic agents are one adjuvant therapeutic agent. In some embodiments, one or more adjuvant therapeutic agents are two adjuvant therapeutic agents. In some embodiments, one or more adjuvant therapeutic agents are three adjuvant therapeutic agents. In some embodiments, one or more adjuvant therapeutic agents are four adjuvant therapeutic agents.

[0159] In some embodiments, one or more adjunctive therapeutic agents include, for example, DNA polymerase inhibitors such as brincedofovir; protein Jumonji inhibitors such as ML-324, dimethyloxaloylglycine; interferon α2 ligand modulators such as interferon α-2b, Alpharekin®, recombinant human interferon α-2b follow-on biologics, Herpferon®, Anterferon®; nicotinic acetylcholine receptor antagonists such as RPI-MN; and virus-specific T-cell therapies such as readily available monoviral specific therapies.Instructions for Use, Pages 33 / 60, 40, CN 122206672 A: Viral T-cell (VST) therapy, ALVR-108, multiviral specific T-cell TI1; other drugs for the treatment of herpesvirus infection, such as BOR-15001L7, lidocaine, lichenstatin-23; or any combination thereof.

[0160] In some embodiments, one or more adjunctive therapeutic agents include, for example, anti-herpesvirus envelope glycoprotein D antibodies, such as m27f; progesterone receptor agonists, such as levonorgestrel; or HIV-1 reverse transcriptase inhibitors, such as tenofovir; or any combination thereof.

[0161] In some embodiments, one or more adjunctive therapeutic agents include, for example, endonuclease modulators, such as broad-spectrum nucleases; interferon α ligand / interferon γ receptor antagonists, such as Anaferon®, or any combination thereof.

[0162] In some embodiments, one or more additional therapeutic agents include, for example, CCR5 chemokine modulators; DNA polymerase inhibitors; DNA primase inhibitors; fatty acid synthase inhibitors; glucocorticoid receptor agonists; helicase inhibitors; herpesvirus envelope glycoprotein D inhibitors; Hsp90 inhibitors; human cytomegalovirus glycoprotein inhibitors; hyaluronidase inhibitors; interferon α1 ligands; interferon α2 ligands; interferon β ligands; T cell surface glycoprotein CD8 stimulators; or cyclin-dependent kinase inhibitors, or any combination thereof.

[0163] In some embodiments, one or more additional therapeutic agents include, for example, DNA primase-helicase inhibitors, such as amonexvir, prepillevivir, IM-250; DNA polymerase inhibitors, such as famciclovir, penciclovir, valacyclovir, acyclovir, sodium phosphonoformate; CCR5 chemokine modulators / human cytomegalovirus glycoprotein inhibitors, such as MB-66; Hsp90 inhibitors, such as BJ-B11; glucocorticoid receptor agonists, such as hydrocortisone; interferon α1 ligand modulators, such as interferon α1b, recombinant human interferon α1b; interferon α2 ligand modulators, such as recombinant human interferon α-2b, KW-045; interferon β ligand modulators, such as interferon β-1a (RebiSmart™); anti-HSV envelope glycoprotein D antibodies, such as UB-621; T Cell surface glycoprotein CD8 stimulators, such as immunogenic peptides; fatty acid synthase inhibitors, such as TVB-2640; anti-herpes simplex virus monoclonal antibodies, such as HDIT-101; or other drugs used to treat herpes simplex virus infection, such as idoxuridine, BTL-TML-HSV, docosyl alcohol, MAR-8644, MAR-8658, NV-HHV-101, PRL-01, HN-0037; or any combination thereof.

[0164] In some embodiments, one or more adjunctive therapeutic agents include, for example, hyaluronidase inhibitors such as astodrimer (SPL-7013); live attenuated HSV vaccines such as RVx-101 HSV-1; live attenuated HSV vaccines with deletions of UL20 and UL53, such as VC2; live attenuated HSV vaccines with mutations in the R2 coding region of UL37, such as R2; or trivalent HSV-2 subunit vaccines (containing gC2, gD2, gE2), such as trivalent HSV-2 vaccines; or any combination thereof.

[0165] In some embodiments, one or more adjunctive therapeutic agents include, for example, live attenuated recombinant vaccines such as AuroVax; HSV-2 replication-deficient vaccines with deletions of UL5 and UL29, such as HSV-529; mRNA vaccines against HSV-2 disease, such as mRNA-1608; or any combination thereof.

[0166] In some embodiments, one or more additional therapeutic agents include, for example, CD4 agonists; CD89 agonists; Duffy antigen chemokine receptor modulators; herpesvirus envelope glycoprotein D inhibitors; HIV gp120 protein inhibitors; HIV gp160 protein inhibitors; HIV gp41 protein inhibitors; immunoglobulin G agonists; nicotinic acetylcholine receptor antagonists; TAT protein modulators; T cell surface glycoprotein CD8 stimulators; or TLR-4 agonists; or any combination thereof.

[0167] In some embodiments, one or more additional therapeutic agents include, for example, nicotinic acetylcholine receptor antagonists such as RPI-78M; anti-herpes simplex virus monoclonal antibodies such as HDIT-101; anti-herpes virus envelope glycoprotein D antibodies such as UB-621; TLR-4 agonists such as IDC-G103 vaccine; inactivated HSV-1 and HSV-2 vaccines such as Vitaherpavac®; inactivated HSV-1 and HSV-2 vaccines such as Theravax-HSV-2 vaccine; formalin-inactivated herpesvirus (FI-HSV2) vaccine; or RBT-26 T cell-based subunit vaccines; DNA vaccines such as pDNA / rVSV vector vaccines; or other drugs for treating HSV-2 such as EBT-105, Alloferon™; or any combination thereof. Instructions for Use, pages 34 / 60, 41 CN 122206672 A

[0168] In some embodiments, one or more additional therapeutic agents include, for example, HIV gp120 / gp160 / gp41 protein inhibitors, such as griffithsin; hyaluronidase inhibitors, such as atorvastatin (SPL-7013); CD4Agonist / T-cell surface glycoprotein CD8 vaccine, such as GENO-2; TAT protein modulator, such as HerpesVaxTat® vaccine; CD89 agonist / Duffy antigen chemokine receptor modulator / immunoglobulin G agonist, such as glycoprotein D+ liposome-encapsulated glycoprotein D booster vaccine; or vaccine, such as Profavax-HSV-2 vaccine; HSV-2 mRNA vaccine; glycoprotein D DNA vaccine; or any combination thereof.

[0169] In some embodiments, one or more additional therapeutic agents include, for example, DNA vaccines, such as the HSV-2 vaccine Admedus; RNA vaccines, such as GSK-4108771A; live attenuated virus vaccines, such as EXD-12; live attenuated virus vaccines based on δ-gD2; vaccines, such as NE-gD2 adjuvanted HSV-2 vaccines based on intranasal nanoemulsion NE; or other medicines for treating HSV-2, such as EBT-105, Alloferon™; or any combination thereof.

[0170] In some embodiments, one or more additional therapeutic agents include, for example, antimicrobial peptides; CD4 modulators; CRISPR-associated endonuclease Cas9 modulators; cyclin-dependent kinase-9 inhibitors; DNA polymerase inhibitors; nicotinic acetylcholine receptor antagonists; TAT protein modulators; thymidine kinase inhibitors; or viral envelope protein inhibitors; or any combination thereof.

[0171] In some embodiments, one or more additional therapeutic agents include, for example, DNA polymerase inhibitors / thymidine kinase inhibitors, such as acyclovir; CRISPR-associated endonuclease Cas9 modulators, such as EBT-104; nicotinic acetylcholine receptor antagonists, such as RPI-78M; cyclin-dependent kinase-9 inhibitors, such as FIT-039; other drugs for the treatment of HSV-1, such as ZEP-3Na, MXB-009; CD4 modulator peptide vaccines, such as CEL-1000; vaccines, such as inactivated HSV-1 and HSV-2 vaccines, such as Vitaherpavac® (anti-herpes vaccine); inactivated HSV-1 and HSV-2 vaccines, such as Theravax-HSV-1 vaccine; or viral envelope protein inhibitors, such as MXB-005; or combinations thereof.

[0172] In some embodiments, one or more adjunctive therapeutic agents include, for example, TAT protein modulators, such as HerpesVaxTat® vaccine; or vaccines, such as Profavax-HSV-1 vaccine; or combinations thereof.

[0173] In some embodiments, one or more adjunctive therapeutic agents include, for example, live attenuated virus vaccines, such as EXD-12; or δ-gD2-based live attenuated virus vaccines; or combinations thereof.

[0174] In some embodiments, one or more adjunctive therapeutic agents include, for example, DNA polymerase inhibitors; herpesvirus envelope glycoprotein D inhibitors; or interferon α2 ligands; or combinations thereof.

[0175] In some embodiments, one or more adjunctive therapeutic agents include, for example, DNA polymerase inhibitors such as famciclovir, penciclovir; interferon α2 ligand modulators such as Yallaferon®; anti-herpesvirus envelope glycoprotein D antibodies such as UB-621; or other drugs for the treatment of genital herpes, such as interferon γ, Alloferon™, ZEP-3Na; or combinations thereof.

[0176] In some embodiments, one or more adjunctive therapeutic agents include, for example, vaccines such as NE-gD2 adjuvanted vaccines based on intranasal nanoemulsion NE; or other drugs for the treatment and prevention of genital herpes, such as SQX-77, anti-STI antibodies; or combinations thereof.

[0177] In some embodiments, one or more adjunctive therapeutic agents include, for example, herpes vaccines based on SAPN (self-assembled protein nanoparticles).

[0178] In some embodiments, one or more additional therapeutic agents include, for example, a CMV 65kDa lower matrix phosphoprotein modulator; a DNA polymerase inhibitor; a G protein-coupled receptor homolog US28 antagonist; a herpesvirus envelope glycoprotein B stimulator; an HLA class I antigen A-11α modulator; an HLA class I antigen A-2α modulator; an HLA class I antigen A-24α modulator; a human cytomegalovirus glycoprotein B inhibitor; a human cytomegalovirus glycoprotein B modulator; a human cytomegalovirus glycoprotein H modulator; a human cytomegalovirus glycoprotein inhibitor; a large terminal enzyme protein inhibitor; a ribonuclease stimulator; a serine-threonine protein kinase UL97 modulator; a synaptic fusion protein-5 inhibitor; a transferase inhibitor; or a viral ribonucleotide reductase inhibitor; or a combination thereof.

[0179] In some embodiments, one or more adjunctive therapeutic agents include, for example, DNA polymerase inhibitors such as ganciclovir, fomivir, fomivir sodium, valganciclovir; DNA polymerase inhibitors / serine-threonine protein kinase UL97 modulators such as filociclovir; G protein-coupled receptor homolog US28 antagonists such as SYN-002; large terminal enzyme protein inhibitors such as AIC-387, AIC-476; serine-threonine protein kinase UL97 inhibitors such as maribavir; viral ribonucleotide reductase inhibitors such as didox; ribonuclease stimulators such as ranpirnase; HLA class I antigen A-11α modulators / HLA class I antigen A-2α modulators / HLA class I antigen A-24α modulators, such as allogeneic anti-CMV-TCR-T cell therapy, YT-CMV-22, YT-CMV-27, and YT-CMV-45; human cytomegalovirus glycoprotein B inhibitors, such as CMV-345; other drugs for the treatment of CMV, such as USC-505, USC-596, CMV pp65 and ppM83 derived peptides, artemifone (BAY-44-9585), PG-36, CMX-16669, HN-0141, ALVR-105, NPP-669, CMV pH4 human immunoglobulin, Cytovir™, antiviral cytotoxic T cell therapy, CMV TCR-transduced T cells, and adimlecleucel; or polyclonal antibodies, such as Cytogam®; or combinations thereof.

[0180] In some embodiments, one or more additional therapeutic agents include, for example, a synaptic fusion protein-5 inhibitor, such as Retro-94; a large terminal enzyme protein inhibitor, such as lemetmovir; a DNA polymerase inhibitor, such as valganciclovir; an anti-CMV antibody, such as BT-084 (Cytotect® CP); a human cytomegalovirus glycoprotein B and glycoprotein H modulator vaccine, such as mRNA-1647; a CMV 65kDa lower matrix phosphoprotein vaccine, such as IRB-12022; or a vaccine, such as an mRNA-based vaccine; a BD-03 plasmid DNA vaccine; a V-212 heat-treated varicella-zoster virus vaccine; a protein subunit vaccine, such as VBI-1501A; a CMV-MVA pentameric vaccine (RhUL128C-MVA); a CMV-MVA trivalent vaccine; a VLP-based vaccine SPYVLP-102; or any combination thereof.

[0181] In some embodiments, one or more adjunctive therapeutic agents include, for example, human cytomegalovirus glycoprotein inhibitors, such as CMV-IVIG; adjunctive medicines for the treatment or prevention of CMV, such as artemisinin derivatives, NPC-21; herpesvirus envelope glycoprotein B stimulating vaccines, such as HB-101; CMV 65kDa lower matrix phosphoprotein modulator vaccines, such as AVX-601; vaccines, such as CMV vaccines; CMV pp65 peptide vaccines; V-160; or multivirus-specific cytotoxic T-cell therapies; or any combination thereof.

[0182] In some embodiments, one or more adjunctive therapeutic agents include, for example, DNA polymerase inhibitors, such as ganciclovir, fomivir, cidofovir, valganciclovir, sodium phosphonate.

[0183] In some embodiments, one or more additional therapeutic agents include, for example, DNA polymerase inhibitors; helicase inhibitors; immunoglobulin agonists; interferon α2 ligands; interferon α ligand modulators; interferon β ligands; or TLR-4 agonists; or any combination thereof.

[0184] In some embodiments, one or more additional therapeutic agents include, for example, DNA polymerase inhibitors such as penciclovir, famciclovir, valacyclovir, acyclovir, USC-373; DNA primase inhibitors-helicase inhibitors such as amonexvir; interferon α2 ligand modulators such as interferon α-2b, Yallaferon®, pegylated interferon α-1b, INTEFEN®, interferon α-2a, Anterferon®; interferon β ligand modulators such as RebiSmart™; immunoglobulin agonists such as Varicellon®, shingles immunoglobulin-VF; vaccines such as varicella vaccine (live attenuated vaccine); MMRV vaccine; shingles vaccine; recombinant adjuvant shingles vaccine; or medicines for treating varicella-zoster virus infection such as HerpeCide™; or any combination thereof.

[0185] In some embodiments, one or more adjunctive therapeutic agents include, for example, vaccines such as ProQuad®; Priorix-Tetra® (MeMuRu-OKA); protein subunit TLR-4 agonist vaccines such as CRV-101; vaccines based on the VZV ORF29 mutant; varicella vaccines (live attenuated vaccines); Sinovac varicella vaccine; Varilrix® vaccine (VZV-OKA strain); attenuated recombinant subunit vaccines containing gE, such as GSK-137173A; protein subunit vaccines such as SP-0204; pneumococcal conjugate vaccines such as SP-0202; triple live attenuated vaccines such as M-M-RvaxPRO®; adenovirus vector vaccines such as VTP- 400; recombinant varicella-zoster virus vaccine; recombinant shingles vaccine; inactivated varicella-zoster vaccine; live attenuated virus vaccine, such as NBP-608, Suduvax® II, VZV-7D; or anti-varicella-zoster virus antibody, such as VariZIG®; or any combination thereof.

[0186] In some embodiments, one or more adjunctive therapeutic agents include, for example, drugs for treating or preventing varicella-zoster virus infection, such as OV-02; or vaccines, such as EG-HZ; or any combination thereof.

[0187] In some embodiments, one or more adjunctive therapeutic agents include, for example, interferon α2 ligand; DNA polymerase inhibitor; transferase inhibitor; CRISPR-associated endonuclease Cas9 modulator; LAT gene inhibitor; or gene inhibitor; or any combination thereof.

[0188] In some embodiments, one or more adjunctive therapeutic agents include, for example, DNA polymerase inhibitors, such as acyclovir.Lovir, ganciclovir; interferon α2 ligand modulators, such as interferon α-2b, Anterferon®; CRISPR-associated endonuclease Cas9 modulators / gene inhibitors, such as HSV-1-targeted CRISPR / Cas9 gene therapy; LAT gene inhibitors, such as IFNγ / LAT siRNA gene therapy (rdHSV1 vector, herpes simplex keratitis); adjunctive therapies for the treatment of herpes simplex keratitis, such as EKC-Cide™; or any combination thereof.

[0189] In some embodiments, one or more additional therapeutic agents include, for example, a Basigin inhibitor; an envelope glycoprotein GP350 modulator; an Epstein-Barr nuclear antigen 1 inhibitor; an Epstein-Barr nuclear antigen 1 stimulator; an HLA class I antigen A-11α modulator; an HLA class I antigen A-2α modulator; an HLA class I antigen A-24α modulator; a human cytomegalovirus glycoprotein B modulator; a human cytomegalovirus glycoprotein H modulator; a human cytomegalovirus glycoprotein L modulator; a latent membrane protein 1 modulator; a latent membrane protein 2 stimulator; an NKG2D ligand modulator; or a secretory protein BARF1 modulator; or any combination thereof.

[0190] In some embodiments, one or more adjunctive therapeutic agents include, for example, NKG2D ligand modulators such as pamidronate; Epstein-Barr nuclear antigen 1 inhibitors such as VK-2019, anti-Epstein-Barr virus (EBV) peptides; HLA class I antigen A-11α / HLA class I antigen A-2α / HLA class I antigen A-24α modulators such as allogeneic anti-EBV-TCR-T cells, YT-EBV-44; adjunctive drugs for EBV treatment such as ALVR-105, antiviral cytotoxic T-cell therapy; Epstein-Barr nuclear antigen / latent membrane protein 1 and protein 2 / secretory protein BARF1 modulators such as baltaleucel-T CMD-003; or mRNA vaccines such as mRNA-1195; or any combination thereof.

[0191] In some embodiments, one or more adjunctive therapeutic agents include, for example, basigin modulators, such as EBV gH / gL / gp42 vaccines; or basigin modulators / enveloped glycoprotein GP350 modulators / human cytomegalovirus glycoprotein B modulators / human cytomegalovirus glycoprotein H modulators / human cytomegalovirus glycoprotein L modulators, such as mRNA-1189 vaccines; vaccines, such as EBV gH / gL vaccines; P-989; mRNA vaccines; or EBV cancer vaccines (mRNA, LPP nanoparticles); or any combination thereof.

[0192] In some embodiments, one or more adjunctive therapeutic agents include, for example, Epstein-Barr nuclear antigen 1 / potentialEntomopathic protein 2 stimulators, such as MVA-based vaccines; multivirus-specific cytotoxic T-cell therapies; or vaccines, such as EBV-VLP vaccines; or any combination thereof.

[0193] In some embodiments, one or more adjunctive therapeutic agents include, for example, DNA polymerase inhibitors.

[0194] In some embodiments, one or more adjunctive therapeutic agents include, for example, DNA polymerase inhibitors, such as brincidofovir; drugs for the treatment of herpesvirus type 6, such as ALVR-105; multivirus-specific cytotoxic T-cell therapies; or HHV-6B glycoprotein complex gH / gL / gQ1 / gQ2 subunit vaccines; or any combination thereof.

[0195] Examples include the following examples to illustrate specific embodiments of the present disclosure. It will be understood by those skilled in the art that the techniques disclosed in the following examples represent techniques that are fully functional in the practice of the present disclosure and can therefore be considered as specific patterns constituting the practice thereof. However, it will be understood by those skilled in the art that these examples are exemplary and not exhaustive in accordance with the present disclosure. Many changes may be made to the specific embodiments disclosed herein without departing from the spirit and scope of this disclosure and similar or analogous results may still be obtained.

[0196] The compounds disclosed herein may be prepared using suitable materials according to the procedures of the following schemes and examples, and are further illustrated by the following specific examples. In addition, additional compounds of this disclosure claimed herein may be readily prepared by utilizing the procedures described herein in conjunction with common techniques in the art. The examples also illustrate details for the preparation of the compounds of this disclosure. Those skilled in the art will readily understand that known variations of the conditions and methods of the following preparation procedures may be used to prepare these compounds. For the synthesis of compounds of the embodiments described in this disclosure, examination of the structure of the compound to be synthesized will provide identification of each of the substituent groups. In some cases, given the examples herein, the identification of the final product may make the identification of the obvious starting material apparent by examining the process. The compounds may be isolated in the form of their pharmaceutically acceptable salts, such as those described above. The compounds described herein are generally stable and separable at room temperature and pressure.

[0197] The following illustrates the preparation of the compounds disclosed herein. Unless otherwise stated, variables have the same meaning as above. The examples presented below are intended to illustrate specific embodiments of this disclosure. Suitable starting materials, structural units, and reagents used in the synthesis described below are commercially available from companies such as AbovChem, Acros Organics, Astatech, Combi Blocks, Oakwood Chemical, or Sigma-Aldrich.They can be obtained, or routinely prepared using procedures described in the literature, such as in "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 5th edition; John Wiley & Sons or T. Eicher, S. Hauptmann, "The Chemistry of Heterocycles; Structures, Reactions, Synthesis and Application", 2nd edition, Wiley-VCH, 2003; and Fieser et al., "Fiesers' Reagents for Organic Synthesis", John Wiley & Sons 2000.

[0198] List of Abbreviations and Acronyms Abbreviation / Acronymation Meaning Ac Acetate AcOH Acetic acid aq. Aqueous solution Ar Argon Bn Benzyl BnSH Benzyl mercaptan Boc Tert-butoxycarbonyl Boc2O Di-tert-butyl dicarbonate Bu4N Tetrabutylammonium chloride DCM Dichloromethane DIEA or DIPEA N,N-Diisopropylethylamine DMAP 4-Dimethylaminopyridine DMF N,N-Dimethylformamide Specification 38 / 60 pages 45 CN 122206672 A DMSO Dimethyl sulfoxide eq. or equiv Et Ethyl Et3N Triethylamine EtOAc Ethyl acetate h or hr(s) Hourly HPLC High-performance liquid chromatography i-Pr Isopropyl LCMS Liquid chromatography-mass spectrometry Me Methyl MeOH Methanol MPLC Medium-pressure liquid chromatography MS Mass spectrometry m / z Mass-charge ratio NMR Nuclear magnetic resonance spectroscopy PhMe Toluene RT or rt Room temperature, sat. or satd., saturated SFC, supercritical fluid chromatography, t-Bu or tBu, tert-butyl TCFH, chloro(dimethylamino)-N,N-dimethylmethaneimine hexafluorophosphate, TFA, trifluoroacetic acid, THF, tetrahydrofuran. General procedure A: Step 1 (amide coupling): Add N-methylimidazolium (2.2 equivalents) to a solution of A.1 type indoline (1 equivalent), A.2 type carboxylic acid (1 equivalent), and chloro-N,N,N',N'-tetramethylformamidin hexafluorophosphate (1.1 equivalent) in MeCN (0.05 M) at 0 °C. Heat the reaction mixture to room temperature for 2 hours. Dilute the reaction mixture with water and extract with ethyl acetate. Wash the combined organic fractions with brine, dry over Na2SO4, filter, and concentrate under reduced pressure to obtain the residue. Redissolve the residue again.In DCM, silica gel was added. The resulting mixture was concentrated under reduced pressure to obtain a flowing solid, which was purified by silica gel rapid chromatography (0% to 50% EtOAc / hexane) to obtain the A.3 type coupling product. Specification 39 / 60 pages 46 CN 122206672 A

[0199] Step 2 (deprotection): The A.3 type amide obtained in Step 1 was dissolved in DCM (0.05M). Trifluoroacetic acid (8 equivalents) was added to the solution at room temperature, and the reaction was stirred for 2 hours. The reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by reversed-phase HPLC to obtain the desired A.4 type product.

[0200] Preparation of Intermediate 1: Preparation of Intermediate 1.1: Diethyl carbonate (86 mL, 1.5 equivalents) was added to a stirred suspension of mineral oil (22.72 g, 2 equivalents) containing 60% NaH in 1000 mL of THF at 0 °C. 5-Bromo-indan-1-one (100 g, 473.1 mmol) was added in portions at this temperature. The reaction mixture was stirred at this temperature until the gas escaped and dissipated. The reaction mixture was slowly heated to 50 °C and stirred for 2 hours. The reaction progress was monitored by TLC, and the reaction mixture was cooled to room temperature after the initial material was consumed. The reaction was diluted with EtOAc (10V). 3N HCl aqueous solution was added dropwise. The two layers were separated. The aqueous layer was extracted with EtOAc (2×5V). The combined organic layer was washed with brine (5V), dried (Na2SO4), and evaporated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain intermediate 1.1. LC / MS: 283.0 [M+H]+.

[0201] Preparation of intermediate 1.2: Triethylsilane (224mL) was added dropwise to a solution of intermediate 1.1 (56g, 197.9mmol) in TFA (280mL) at 0°C, and the reaction mixture was stirred at room temperature for 24 hours. The reaction progress was monitored by TLC. After the starting material was consumed, the reaction mixture was evaporated to dryness under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain intermediate 2.2. LC / MS: 269.0 [M+H]+.

[0202] Intermediate 1 Preparation of .3: The stirred solution of intermediate 1.2 (40 g, 148.7 mmol) and 2-tributyltinylpyridine (57.5 g, 1.05 equivalence) in 1,4-dioxane (400 mL) was degassed with argon for 10 min, at which point Pd(PPh3)4 (8.6 g, 5 mol%) was added and degassed again for another 10 min. The reaction mixture was heated to 90 °C for 16 h. The reaction mixture was then subjected to argon degassing.The mixture was filtered through a diatomaceous earth pad, and the diatomaceous earth pad was washed twice with ethyl acetate. The combined filtrates were evaporated to dryness to give the crude product. The crude product was purified by silica gel column chromatography to give intermediate 1.3. LC / MS: 268.1 [M+H].

[0203] Preparation of intermediate 1.4: 2N NaOH aqueous solution (140 mL, 2.2 equivalents) was added to a stirred solution of intermediate 1.3 (35 g, 131.1 mmol) in methanol (350 mL) at 0 °C, and the reaction mixture was stirred at room temperature for 4 hours. After the reaction was complete, the reaction mixture was concentrated to 100 mL under reduced pressure. The residue was diluted with water (10 V), and the aqueous layer was washed with ethyl acetate (2 × 2 V). The aqueous phase was neutralized with 2N HCl aqueous solution and extracted with 10% methanol / DCM (3 × 5 V). The organic layer was dried over sodium sulfate and concentrated to give the crude product. The crude product was then dissolved in 10% IPA / toluene (10 V) solution and treated with activated carbon. The solvent was then removed under reduced pressure. The residue was dissolved in a 30% toluene / hexane mixture, stirred for 30 minutes, filtered, and then dried under vacuum. This process was repeated twice to give intermediate 1.4. LC / MS: 238.1 [M-H]-.

[0204] Intermediate 1 was obtained as the first eluent during SFC purification of intermediate 1.4 using a Chiralpak AD-H column with 20% methanol as a co-solvent. LC / MS: 238.1 [M-H]-.

[0205] Preparation of Intermediate 2: See page 40 / 60 of the specification, CN 122206672 A. Preparation of Intermediate 2.1: At 0 to 15°C under a N2 atmosphere, K2CO3 (165 g, 1.2 equivalents) was added to a stirred solution of 5-bromo-2-hydroxybenzaldehyde (201 g, 1 mol) in DMF (10 V), followed by the addition of ethyl bromoacetate (183 g, 1.1 equivalents). The resulting mixture was stirred at room temperature for 20 hours, then filtered and the solid was washed with EtOAc. The combined filtrate was quenched with ice-cold water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over sodium sulfate, and concentrated by distillation to give intermediate 2.1 as a yellow solid, which was used in the next step without further purification. LC / MS: 285.0 [M-H]-.

[0206] Preparation of intermediate 2.2: At 0°C and under a N2 atmosphere, NaBH4 (26 g, 1.3 equivalents) was added in portions to a stirred solution of intermediate 2.1 (150 g, 0.52 mol) in THF (10 V). The reaction mixture was heated to room temperature for 2 hours, during which ice water was added, and the mixture was extracted with EtOAc. The combined organic fractions were washed with water and brine solution and subjected to sulfur dioxide treatment.The sodium sulfate was dried and concentrated by distillation to obtain a crude product. The crude product was ground with n-pentane to obtain intermediate 2.2, which was used in the next step without further purification. LC / MS: 287.0 [M-H]-.

[0207] Preparation of intermediate 2.3: SOCl2 (66 mL, 1.5 equivalents) was added to a stirred solution of intermediate 2.2 (175 g, 0.61 mol) in DCM (10 V) at 0 °C under N2 atmosphere. The reaction mixture was stirred at room temperature for 2 hours, during which time it was quenched with saturated NaHCO3 aqueous solution and extracted with DCM. The combined organic layers were washed with brine, dried with anhydrous sodium sulfate and concentrated by distillation to obtain a crude product. The crude product was purified by column chromatography (silica gel: 100 to 200 mesh; eluent: 2% to 3% EA / PE) to obtain intermediate 2.3. LC / MS: 305.0 [M-H]-.

[0208] Preparation of intermediate 2.4: t-BuOK (76.6 g, 1.4 equivalents) was added in a single batch to a stirred solution of intermediate 2.3 (150 g, 380 mmol) in THF (30 V) at 0 °C under a N2 atmosphere. The reaction mixture was stirred at room temperature for 2 hours, during which time it was quenched with a saturated NH4Cl aqueous solution and extracted with EtOAc. The combined organic layers were washed with a brine solution, dried over anhydrous sodium sulfate, and concentrated by distillation to obtain the crude product. The crude product was purified by column chromatography (silica gel: 100 to 200 mesh; eluent: about 0% to 5% EA / PE) to obtain intermediate 2.4. LC / MS: 269.0 [M-H]-.

[0209] Preparation of intermediate 2.5: 2-(tributyltinyl)pyridine was added to a degassed solution of intermediate 2.4 (40 g, 148 mmol) in toluene (12 V) at room temperature, followed by the addition of Pd(PPh3)4 at room temperature. The resulting solution was degassed again with argon for 2 minutes. The reaction mixture was heated to 80 °C for 16 hours, then cooled to room temperature, diluted with EtOAc, stirred for 30 minutes, and filtered through a diatomaceous earth mat. The diatomaceous earth mat was washed twice with EtOAC. The combined filtrates were concentrated under vacuum by distillation to obtain a crude product. The crude product was purified by column chromatography (silica gel: 100 to 200 mesh; eluent: 5% EA / PE) to obtain intermediate 2.5. LC / MS: 270.1 [M+H]+. Instructions for Use, pages 41 / 60, CN 122206672 A

[0210] Preparation of Intermediate 2.6: LiOH·H2O (21.1 g, 3 equivalents) was added to a stirred solution of intermediate 2.5 (45 g, 167 mmol) in a mixture of THF and H2O (10 V, approximately 1:1 ratio) at room temperature. The reaction mixture was stirred at room temperature.Stir for 2 hours, during which time THF is evaporated from the reaction mixture, and the remaining aqueous layer is washed twice with EtOAc. The aqueous layer is acidified with concentrated HCl to a pH of about 4 to 5 and stirred at 0 to 10°C for 30 minutes. The precipitated solid is filtered and dried under reduced pressure to give hydrochloride intermediate 2.6. LC / MS: 240.1 [M-H]-.

[0211] Intermediate 2 was obtained as the first eluent during SFC separation using a ChiralART cellulose SZ (C2) (250×30×5µm) column with 30% (0.5% dimethylamine / methanol) as the co-solvent.

[0212] Preparation of Intermediate 3: Preparation of Intermediate 3.1: Sodium cyanoborohydride (8.8 g, 140.2 mmol, 2 equivalents) was added to a solution of 6-bromo-5-fluoro-1H-indole (15 g, 70.1 mmol, 1 equivalent) in AcOH (150 mL) at 0 °C under a N2 atmosphere. The reaction mixture was then heated to 25 °C and stirred for 1 hour. The reaction mixture was diluted with water (100 mL), neutralized to pH 8 with NaOH, extracted with EtOAc (100 mL × 2), and the combined organic phases were washed with brine (150 mL), dried over Na2SO4 and shrunk under vacuum to obtain a residue. The residue was dissolved in DCM (60 mL) and 30 g of silica gel was added. The resulting mixture was concentrated under reduced pressure to obtain a flowing solid, which was then purified by silica gel rapid chromatography (10% to 15% ethyl acetate / petroleum ether) to obtain Intermediate 3.1. LC / MS: 216.0 [M+H]+.

[0213] Preparation of intermediate 3.2: At 0°C, 23.4 g (90.3 mmol, 1 equivalent) of 2,5-dioxopyrrolidone-1-yl)-trimethylsilyl ethyl carbonate and 18.3 g (180.5 mmol, 25.1 mL, 3 equivalent) were added to a solution of intermediate 3.1 (13 g, 60.2 mmol, 1 equivalent) in DCM (150 mL). The reaction mixture was stirred at 25°C for 22 hours. The reaction mixture was diluted with water (150 mL) and extracted with ethyl acetate (150 mL × 2). The combined organic phases were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in DCM (100 mL) and 26 g of silica gel was added. The resulting mixture was concentrated under reduced pressure to obtain a flowing solid, which was then purified by silica gel rapid chromatography (10% to 15% ethyl acetate / petroleum ether) to obtain intermediate 3.2. LC / MS: 360.0 [M+H]+.

[0214] Preparation of intermediate 3.3: Intermediate 3.2 (6.5 g, 18.0 mmol, 1 equivalent) was dissolved in dioxane (70 mL)DIPEA (4.7 g, 36.1 mmol, 6.3 mL, 2 equivalents), Xantphos (1.0 g, 1.8 mmol, 0.1 equivalents), Pd2(dba)3 (826.0 mg, 902.0 μmol, 0.05 equivalents), and ethyl 3-mercaptopropionate (7.3 g, 54.1 mmol, 3 equivalents) were added to the solution. The reaction mixture was stirred at 100 °C for 16 hours. The reaction mixture was diluted with water (70 mL) and extracted with ethyl acetate (50 mL × 2). The combined organic phases were washed with brine (70 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in DCM (70 mL) and 13 g of silica gel was added. The resulting mixture was concentrated under reduced pressure to obtain a flowing solid, which was then purified by silica gel rapid chromatography (5% to 10% ethyl acetate / petroleum ether) as described on pages 42 / 60 of the specification (CN 122206672 A) to obtain intermediate 3.3. LC / MS: 414.1 [M+ H]+.

[0215] Preparation of intermediate 3.5: At 0°C and under a N2 atmosphere, t-BuOK (814.0 mg, 7.3 mmol, 1.5 equivalent) was added to a solution of intermediate 3.3 (2 g, 4.8 mmol, 1 equivalent) in THF (20 mL), and the mixture was stirred at 25°C for 1 hour to obtain crude intermediate 3.4. In the same flask, at 0°C and under a N2 atmosphere, iodoethane (2.3 g, 14.5 mmol, 1.2 mL, 3 equivalent) was added to the mixture, and the solution was stirred at 25°C for 15 hours. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (25 mL × 2). The combined organic phases were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain a residue. The residue was dissolved in DCM (20 mL) and 2 g of silica gel was added. The resulting mixture was concentrated under reduced pressure to obtain a flowing solid, which was then purified by silica gel rapid chromatography (0% to 5% ethyl acetate / petroleum ether) to give intermediate 3.5. LC / MS: 342.1 [M+H]+.

[0216] Preparation of intermediate 3.6: m-CPBA (653.9 mg, 3.2 mmol, 85% purity, and 1.1 equivalent) was added to a solution of intermediate 3.5 (1 g, 2.9 mmol, 1 equivalent) in DCM (10 mL) at -30 °C. After stirring at -30 °C for 1 hour, the reaction mixture was quenched with saturated Na2SO3 aqueous solution (30 mL) and extracted with DCM (10 mL × 2). The combined organic phases were washed with saturated NaHCO3 aqueous solution (10 mL) and brine (10 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give intermediate 3.6. LC / MS: 358.1 [M+H]+.

[0217] Preparation of intermediate 3.7: Rhodium diacetoxy (92 mg, 209.8 μmol, 0.06 equivalent), MgO (1.1 g, 28.0 mmol, 314.9 μL, 8 equivalent), and tert-butyl carbamate (1.2 g, 10.5 mmol, 3 equivalent) were added to a solution of intermediate 3.6 (1.3 g, 3.5 mmol, 3 equivalent) in DCM (15 mL). PIDA (4.5 g, 14.0 mmol, 4 equivalent) was then added dropwise to the mixture and stirred at 20 °C for 12 hours. The reaction was filtered, and the filtrate was quenched with saturated (aqueous) Na2SO3 (20 mL) and extracted with DCM (20 mL × 2). The combined organic phases were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was dissolved in DCM (20 mL) and 1 g of silica gel was added. The resulting mixture was concentrated under reduced pressure to obtain a flowing solid, which was then purified by rapid silica gel chromatography (15% to 20% ethyl acetate / petroleum ether) to give intermediate 3.7. LC / MS: 473.2 [M+H]+.

[0218] Preparation of intermediate 3: TBAF (1M, 4.2mL, 5 equivalents) was added to a solution of intermediate 3.7 (400mg, 846.3μmol, 1 equivalent) in THF (4mL), and the mixture was stirred at 50°C for 2 hours. The reaction mixture was diluted with water (5mL) and extracted with ethyl acetate (5mL×2). The combined organic phases were washed with brine (5mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by rapid column chromatography (10% to 50% ethyl acetate / petroleum ether) to give intermediate 3. LC / MS: 329.1 [M+H]+.

[0219] The following intermediates were prepared in a manner similar to intermediate 3, with thioalkylation using appropriate indoline and alkyl halide as needed. Specification 43 / 60 pages 50 CN 122206672 A

[0220] Preparation of intermediate 8: Preparation of intermediate 8.1: At 0°C under a N2 atmosphere, t-BuOK (813.9 mg, 7.2 mmol, 1.5 equivalent) was added to a solution of intermediate 3.3 (2 g, 4.8 mmol, 1 equivalent) in THF (20 mL), and the mixture was stirred at 20°C for 1 hour to obtain intermediate 3.4. Then, at 0°C under a N2 atmosphere, MeI (2.0 g, 14.5 mmol, 903.1 μL, 3 equivalent) was added to the mixture, and the mixture was stirred at 20°C for 15 hours. LCMS showed complete consumption of the starting material and detection of approximately 72% of the compound with the desired molecular weight. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 2).Take. Wash the combined organic phases with brine (20 mL), dry with Na2SO4, filter and concentrate under reduced pressure to obtain intermediate 8.1, which can be used in the next step without further purification. LC / MS: 328.1 [M+H]+.

[0221] Using the method used to convert intermediate 3.5 to intermediate 3.7, the preparation of intermediate 8.3 was carried out starting from intermediate 8.1. LC / MS: 459.2 [M+H]+.

[0222] Preparation of intermediate 8.4: At 0 °C under N2 atmosphere, NaH (140.5 mg, 3.5 mmol, 60% in mineral oil, 2 equivalents) was added to a solution of intermediate 8.3 (630 mg, 1.7 mmol, 1 equivalent) in THF (8 mL), and the mixture was stirred at 0 °C for 1 hour. Then iodomethane (1.25 g, 8.8 mmol, 546.9 μL, 5 equivalents) was added, and the mixture was stirred at 20 °C for 15 hours. The reaction mixture was quenched with saturated (aqueous) NH4Cl (20 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give intermediate 8.4, which could be used in the next step without further purification. LC / MS: 373.1 [M+H]+.

[0223] Using intermediate 8.4 as the starting material, intermediate 8 was obtained in a manner similar to intermediate 3. LC / MS: 229.1 [M+H]+. Instructions for Use, Pages 44 / 60, 51, CN 122206672 A

[0224] Preparation of Intermediate 9: Preparation of Intermediate 9.1: Sodium cyanoborohydride (23.2 g, 369.9 mmol, 2 equivalents) was added to a solution of 5-fluoro-1H-indole (25 g, 185.0 mmol, 1 equivalent) in AcOH (220 mL) at 0 °C under N2. The mixture was then stirred at 20 °C for 16 hours. The reaction was diluted with H2O (200 mL) and neutralized to pH 7 with saturated (aqueous) NaHCO3, and then extracted with EtOAc (150 mL × 2). The combined organic phases were washed with brine (150 mL), dried over Na2SO4 and concentrated under vacuum to give Intermediate 9.1, which was used in the next step without further purification. LC / MS: 138.1 [M+H]+.

[0225] Preparation of intermediate 9.2: TEA (27.6 g, 273.4 mmol, 38.1 mL, 3 equivalents) was added to a solution of intermediate 9.1 (12.5 g, 91.1 mmol, 1 equivalent) in DCM (200 mL). Acetyl chloride (14.3 g, 182.3 mmol, 12...) was added at 0 °C.0.9 mL (2 equivalents) was added to the mixture and the mixture was stirred at 20 °C for 1 hour. The reaction mixture was diluted with water (150 mL) and extracted with DCM (200 mL × 2). The combined organic phases were washed with brine (150 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give intermediate 9.2, which could be used directly in the next step without further purification. LC / MS: 180.1 [M+H]+.

[0226] Preparation of intermediate 9.3: A solution of intermediate 9.2 (6 g, 33.5 mmol, 1 equivalent) in HSO3Cl (84.1 g, 722.1 mmol, 48 mL, 21.57 equivalents) was stirred at 50 °C for 16 hours. The reaction mixture was cooled to room temperature and slowly quenched with water (100 mL), filtered, and the filter cake was washed with H2O (20 mL × 3), followed by washing with petroleum ether (20 mL × 3) to give intermediate 9.3. LC / MS: 278.0 [M+H]+.

[0227] Preparation of intermediate 9.4: A solution of intermediate 9.3 (2 g, 7.2 mmol, 1 equivalent) in ethylamine (2 M, 18.1 mL, 5 equivalent) was stirred at 20 °C for 1 hour. The mixture was concentrated under reduced pressure to give intermediate 9.4. LC / MS: 287.1 [M+H]+.

[0228] Preparation of intermediate 9: HCl (12 M, 2 mL, 6.9 equivalent) was added to a solution of intermediate 9.4 (1 g, 3.5 mmol, 1 equivalent) in EtOH (10 mL). The mixture was stirred at 80 °C for 3 hours. The mixture was concentrated under reduced pressure to give intermediate 9. LC / MS: 245.3 [M+H]+.

[0229] Example 1 Preparation of (ethyl(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indololin-6-yl)(imino)-λ6-sulfonone): Example 1 was prepared using general procedure A, with intermediates 1 and 3 as starting materials. 1H NMR (400MHz, DMSO-d6): δ 8.70–8.50 (m, 2H), 7.98–7.80 (m, 4H), 7.39–7.27 (m, 3H), 4.54 (s, 1H), 4.33 (br t, J = 8.6Hz, 2H), 3.73 (br t, J = 8.1Hz, 1H), Specification page 45 / 60 52 CN 122206672 A 3.32-3.18 (m, 8H), 1.08 (t, J= 7.4Hz, 3H) ppm. LC / MS: 450.2 [M+H]+.

[0230] Example 2Preparation of ((R)-ethyl(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indole-2-carbonyl)indololin-6-yl)(imino)-λ6-sulfonone): Example 2 was collected as the first eluent during chiral SFC separation of Example 1 using ChiralPak IH (250×30mm, 10μm; mobile phase: 50% [CO2-MeOH(0.1%NH3-H2O)]). 1H NMR (400MHz, DMSO‑d6): δ 8.70‑8.52 (m, 2H), 8.02‑7.78 (m, 4H), 7.41‑7.27 (m, 3H), 4.54 (s, 1H), 4.34 (br t,J= 8.6Hz, 2H), 3.73 (t,J= 8.0Hz, 1H), 3.31-3.24 (m, 6H), 3.23-3.18 (m, 2H), 1.08 (t,J= 7.3Hz, 3H) ppm. LC / MS: 450.1 [M+H]+.

[0231] Example 3 Preparation of ((S)-ethyl(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indololin-6-yl)(imino)-λ6-sulfonone): Example 3 was collected as the second eluent during chiral SFC separation of Example 1 using ChiralPak IH (250×30mm, 10μm; mobile phase: 50% [CO2-MeOH(0.1%NH3-H2O)]). 1H NMR (400MHz, DMSO‑d6): δ 8.71‑8.50 (m, 2H), 8.04‑7.75 (m, 4H), 7.45‑7.21 (m, 3H), 4.54 (s, 1H), 4.34 (br t,J= 8.5Hz, 2H) , 3.73 (br s, 1H) , 3.35 - 3.25 (m, 2H) , 3.20 (br d,J= 7.3Hz, 2H) , 1.08 (t,J= 7.3Hz, 3H) ppm. LC / MS: 450.0 [M+H]+.

[0232] Example 4 Preparation of (ethyl(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydrobenzofuran-2-carbonyl)indololin-6-yl)(imino)-λ6-sulfonone): Example 4 was prepared using general procedure A, with intermediates 2 and 3 as starting materials. 1H NMR (400MHz, DMSO-d6):δ 8.66-8.48 (m, 2H), 8.01-7.80 (m, 4H), 7.42-7.25 (m, 2H), 6.94 (dd, J = 3.4, 8.4Hz, 1H), 5.81-5.70 (m, 1H), 4.57 (s, 1H), 4.46-4.26 (m, 2H), 3.66-3.50 (m, 2H), 3.30 (br s, 2H), 3.20 (q, J = 7.3Hz, 2H), 1.07 (t, J = 7.4Hz, 3H) ppm. LC / MS: 452.0 [M+H]+.

[0233] Example 5 Preparation of ((S)-ethyl(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydrobenzofuran-2-carbonyl) Specification 46 / 60 pages 53 CN 122206672 A indoline-6-yl)(imino)-λ6-sulfonone): Example 5 was obtained as the first eluent when chiral SFC separation of Example 4 was performed using a REGIS(S,S)WHELK-O1 (250mm×25mm, 10µm) column with 75% EtOH as the co-solvent. 1H NMR (400MHz, DMSO‑d6): δ 8.68‑8.45 (m, 2H), 8.05‑7.79 (m, 4H), 7.43‑7.23 (m, 2H), 6.94 (d,J= 8.5Hz, 1H), 5.75 (t,J= 8.0Hz, 1H) , 4.56 (s , 1H) , 4.46 ‑ 4.28 (m , 2H) , 3.59 (br d ,J= 8.3Hz, 2H) , 3.32 ‑ 3.28 (m, 2H) , 3.20 (q ,J= 7.4Hz, 2H), 1.08 (t,J = 7.3Hz, 3H) ppm. LC / MS: 452.0 [M+H]+.

[0234] Example 6 Preparation of ((R)-ethyl(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydrobenzofuran-2-carbonyl)indoline-6-yl)(imino)-λ6-sulfonone): Example 6 was obtained as the second eluent during chiral SFC separation of Example 4 using a REGIS(S,S)WHELK-O1 (250mm×25mm, 10µm) column with 75% EtOH as the co-solvent. 1H NMR (400MHz, DMSO-d6): δ8.70-8.44 (m, 2H), 8.02-7.79 (m, 4H), 7.42-7.24 (m, 2H), 6.95 (d,J= 8.5Hz, 1H), 5.75 (dd,J= 6.4, 9.8Hz, 1H) , 4.56 (s, 1H) , 4.46 ‑ 4.26 (m, 2H) , 3.67 ‑ 3.51 (m, 2H) , 3.33 ‑ 3.27 (m, 2H) , 3.21 (q ,J= 7.4Hz, 2H) , 1.07 (t,J= 7.4Hz, 3H) ppm. LC / MS: 452.0 [M+H]+.

[0235] Example 7 Preparation of ((5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indololin-6-yl)(imino)(propyl)-λ6-sulfonone): Example 7 was prepared using general procedure A, with intermediates 1 and 4 as starting materials. 1H NMR (400MHz, DMSO-d6): δ 8.56 (td, J = 1.3, 4.8Hz, 1H), 8.48 (d, J = 6.6Hz, 1H), 7.93–7.80 (m, 3H), 7.77 (d, J = 7.9Hz, 1H), 7.36–7.26 (m, 3H), 4.28 (br t, J = 8.5Hz, 2H), 3.67 (br t, J = 7.8Hz, 1H), 3.37-3.13 (m, 8H), 1.57-1.44 (m, 2H), 0.84 (t, J = 7.4Hz, 3H) ppm. LC / MS: 464.2 [M+H]+.

[0236] Example 8 Preparation of ((R)-(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indoline-6-yl)(imino)(propyl)-λ6-sulfonone): Example 8 was obtained as the first eluent during chiral SFC purification of Example 7 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO-d6): δ 8.66–8.56 (m, 2H), 7.95–7.83 (m, 4H), 7.37–7.30 (m, 2H).3H) , 4.52 (s, 1H) , 4.34 (br t,J= 8.4Hz, 2H) , 3.73 (t,J= 8.1Hz, 1H) , 3.37 ‑ 3.25 (m, 6H) , 3.20 ‑ 3.15 (m, 2H) , 1.60 ‑ 1.51 (m, 2H) , 0.89 (t,J= 7.4Hz, 3H) ppm. LC / MS: 464.2 [M+ H]+.

[0237] Example 9 Preparation of ((S)-(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indoline-6-yl)(imino)(propyl)-λ6-sulfonone): Example 9 was obtained as the second eluent during the chiral SFC purification of Example 7 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO‑d6): δ 8.67‑8.56 (m, 2H), 7.96‑7.83 (m, 4H), 7.37‑7.30 (m, 3H), 4.34 (br t,J= 8.6Hz, 2H), 3.73 (quin ,J= 7.9Hz, 1H), 3.35-3.25 (m, 6H), 3.20-3.16 (m, 2H), 1.59-1.51 (m, 2H), 0.89 (t,J= 7.4Hz, 3H) ppm. LC / MS: 464.2 [M+H]+.

[0238] Example 10 Preparation of ((5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydrobenzofuran-2-carbonyl)indoline-6-yl)(imino)(propyl)-λ6-sulfonone): Example 10 was prepared using general procedure A, with intermediates 2 and 4 as starting materials. ¹H NMR (400 MHz, DMSO-d6): δ 8.63–8.40 (m, 2H), 7.93–7.74 (m, 4H), 7.41–7.21 (m, 2H), 7.01–6.87 (m, 1H), 5.68 (dd, J = 5.8, 10.0 Hz, 1H), 4.39– 4.20 (m, 2H), 3.66 - 3.42 (m, 2H), 3.34 - 3.15 (m, 4H), 1.58 - 1.42 (m, 2H), 0.87 - 0.80 (m,3H) ppm. LC / MS: 466.2 [M+H]+.

[0239] Example 11 Preparation of ((S)-(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydrobenzofuran-2-carbonyl)indoline-6-yl)(imino)(propyl)-λ6-sulfonone): Specification 48 / 60 pages 55 CN 122206672 A Example 11 was obtained as the first eluent when chiral SFC purification of Example 10 was performed using a DAICEL CHIRALCEL OJ (250mm×30mm, 10µm) column with 50% (0.1% NH3 / methanol) as the co-solvent. 1H NMR (400MHz, DMSO‑d6): δ 8.64‑8.49 (m, 2H), 8.06‑7.76 (m, 4H), 7.43‑7.23 (m, 2H), 6.94 (d,J= 8.4Hz, 1H), 5.75 (t,J= 8.1Hz, 1H) , 4.55 (s, 1H) , 4.46 ‑ 4.27 (m, 2H) , 3.59 (br d,J= 8.0Hz, 2H) , 3.31 ‑ .3.25 (m, 2H) , 3.21 ‑ 3.15 (m, 2H) , 1.61- 1.47 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H) ppm. LC / MS: 466.0 [M+H]+.

[0240] Example 12 Preparation of ((R)-(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydrobenzofuran-2-carbonyl)indoline-6-yl)(imino)(propyl)-λ6-sulfonone): Example 12 was obtained as the second eluent during chiral SFC purification of Example 10 using a DAICL CHIRALCEL OJ (250 mm × 30 mm, 10 µm) column with 50% (0.1% NH3 / methanol) as the co-solvent. 1H NMR (400MHz, DMSO‑d6): δ 8.63‑8.49 (m, 2H), 8.02‑7.79 (m, 4H), 7.43‑7.21 (m, 2H), 6.94 (d,J= 8.5Hz, 1H), 5.75 (dd ,J= 6.4 , 9.8Hz, 1H) , 4.56 (s , 1H) , 4.47 ‑ 4.25 (m, 2H) , 3.66 ‑ 3.51 (m, 2H) , 3.30 3.31 ‑ .3.25 (m, 2H) ,3.22 ‑ 3.15 (m, 2H) , 1.54 (qd ,J= 7.5, 15.3Hz, 2H) , 0.88 (t,J= 7.4Hz, 3H) ppm. LC / MS: 466.0 [M+H]+.

[0241] Example 13 Preparation of ((5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indoline-6-yl)(imino)(2-methoxyethyl)-16-sulfonone): Example 13 was prepared using general procedure A, with intermediates 1 and 5 as starting materials. 1H NMR (400MHz, DMSO-d6): δ 8.64 (d, J = 4.2Hz, 1H), 8.57 (d, J = 6.6Hz, 1H), 7.99–7.82 (m, 4H), 7.38–7.29 (m, 3H), 4.66 (s, 1H), 4.34 (br) t,J= 8.6Hz, 2H), 3.80-3.68 (m, 1H), 3.66-3.52 (m, 2H), 3.51-3.41 (m, 2H), 3.33-3.19 (m, 6H), 3.08 (s, 3H) ppm. LC / MS: 480.2 [M+H]+.

[0242] Example 14 Preparation of ((R)-(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indole specification 49 / 60 pages 56 CN 122206672 A lin-6-yl)(imino)(2-methoxyethyl)-λ6-sulfonone): Example 14 was obtained as the first eluent during the chiral SFC purification of Example 13 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO‑d6): δ 8.64 (d,J= 4.5Hz, 1H), 8.57 (d,J= 6.6Hz, 1H), 8.00‑7.78 (m, 4H), 7.38‑7.28 (m, 3H) , 4.66 (s , 1H) , 4.34 (br t,J= 8.7Hz, 2H) , 3.74 (quin ,J= 8.0Hz, 1H) , 3.66 ‑ 3.53 (m, 2H) , 3.51 ‑ 3.44 (m, 2H) , 3.33 ‑ 3.20 (m,6H), 3.08 (s, 3H) ppm. LC / MS: 480.1 [M+H]+.

[0243] Example 15 Preparation of ((S)-(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indoline-6-yl)(imino)(2-methoxyethyl)-λ6-sulfonone): Example 15 was obtained as the second eluent during the chiral SFC purification of Example 13 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO‑d6): δ 8.64 (d, J = 4.5Hz, 1H), 8.58 (d, J = 6.7Hz, 1H), 7.98‑7.81 (m, 4H), 7.37‑7.27 (m, 3H), 4.66 (s) , 1H) , 4.34 (br t , J = 8.6Hz, 2H) , 3.74 (quin , J = 8.0Hz, 1H) , 3.66 ‑ 3.52 (m , 2H) , 3.51 ‑ 3.42 (m , 2H) , 3.33‑ 3.19 (m , 6H) , 3.08 (s, 3H) ppm. LC / MS: 480.1 [M+H]+.

[0244] Example 16 Preparation of ((5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydrobenzofuran-2-carbonyl)indoline-6-yl)(imino)(2-methoxyethyl)-λ6-sulfonone): Example 16 was prepared using general procedure A, with intermediates 2 and 5 as starting materials. 1H NMR (400MHz, DMSO-d6): δ 8.60 (d, J = 4.2Hz, 1H), 8.52 (d, J = 6.6Hz, 1H), 8.00 (s, 1H), 7.93–7.78 (m, 3H), 7.38 (d, J = 9.8Hz, 1H), 7.27 (ddd, J = 1 .0, 5.5, 6.6Hz, 1H), 6.94 (dd, J = 3.4, 8.4Hz, 1H), 5.75 (dd, J = 7.5, 8.7Hz, 1H), 4.69 (s, 1H), 4.47-4.24 (m, 2H) , 3.65 ‑ 3.53 (m, 4H) , 3.50 ‑ 3.42(m, 2H), 3.33-3.27 (m, 2H), 3.06 (s, 3H) ppm. LC / MS: 482.2 [M+H]+. Specification 50 / 60 pages 57 CN 122206672 A

[0245] Example 17 Preparation of ((R)-(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydrobenzofuran-2-carbonyl)indoline-6-yl)(imino)(2-methoxyethyl)-λ6-sulfonone): Example 17 was obtained as the first eluent when chiral SFC purification of Example 16 was performed using a DAICEL CHIRALCEL OJ (250mm×30mm, 10µm) column with 50% (0.1% NH3 / methanol) as the co-solvent. 1H NMR (400MHz, DMSO‑d6): δ 8.60 (d , J = 4.8Hz, 1H) , 8.52 (d , J = 6.7Hz, 1H) , 8.00 (s , 1H) , 7.93‑7.78 (m , 3H) , 7.38 (d , J = 9.8Hz, 1H), 7.27 (ddd, J = 1.1, 5.4, 6.6Hz, 1H), 6.95 (d, J = 8.4Hz, 1H), 5.75 (dd, J = 6.4, 9.7Hz, 1H), 4.68 (s, 1H), 4.46 - 4.25 (m, 2H), 3.65-3.52 (m, 4H), 3.50-3.43 (m, 2H), 3.33-3.27 (m, 2H), 3.06 (s, 3H) ppm. LC / MS: 482.0 [M+H]+.

[0246] Example 18 Preparation of ((S)-(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydrobenzofuran-2-carbonyl)indoline-6-yl)(imino)(2-methoxyethyl)-λ6-sulfonone): Example 18 was obtained as the second eluent when chiral SFC purification of Example 16 was performed using a DAICEL CHIRALCEL OJ (250 mm × 30 mm, 10 µm) column with 50% (0.1% NH3 / methanol) as the co-solvent. 1H NMR (400MHz, DMSO‑d6): δ 8.60 (br d , J = 4 .3Hz , 1H) , 8.52 (d , J = 6 .6Hz , 1H) , 8.01 (s , 1H) , 7 .93‑ 7 .78 (m , 3H) , 7.38 (br d , J = 9.9Hz, 1H) , 7 .32 ‑ 7 .21 (m, 1H) , 6.94 (d, J = 8.4Hz, 1H) , 5.75 (t, J = 7.9Hz, 1H) , 4.68 (s, 1H) , 4.47 ‑ 4 .27 (m, 2H), 3.64-3.52 (m, 4H), 3.51-3.41 (m, 2H), 3.33-3.27 (m, 2H), 3.06 (s, 3H) ppm. LC / MS: 482.0 [M+H]+.

[0247] Example 19 Preparation of cyclopropyl (5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indoline-6-yl)(imino)-λ6-sulfonone): Example 19 was prepared using general procedure A, with intermediates 1 and 6 as starting materials. 1H NMR (400MHz, DMSO-d6): δ 8.65-8.62 (m, 1H), 8.56 (d, J = 6.6Hz, 1H), 7.96-7.83 (m, 4H), 7.37-7.30 (m, 3H), 4.53 (s, 1H) , 4.33 (br t, J = 8.5Hz, 2H) , 3.77 ‑ 3.69 (m, 1H) , 3.28 (br d , J = 6.2Hz, 6H) , 2.82 ‑ 2.75 (m, 1H) , 1.02 ‑ 0.88 (m, 4H) ppm. LC / MS: 462.1 [M+H]+.

[0248] Example 20 Preparation of ((R)-cyclopropyl(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indole-2-carbonyl)indoline-6-yl)(imino)-λ6-sulfonone): Example 20 was obtained as the first eluent during the chiral SFC purification of Example 19 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO‑d6): δ 8.64 (d, J = 4.3Hz, 1H), 8.56 (d, J = 6.5Hz, 1H), 7.95‑7.84 (m, 4H), 7.37‑7.30 (m, 3H), 4.53(s , 1H) , 4.33 (br t , J = 8.4Hz, 2H) , 3.73 (br t , J = 8.0Hz, 1H) , 3.31 ‑ 3.21 (m, 6H) , 2.79 (br t , J = 4.3Hz, 1H) , 1.06 ‑ 0.90 (m, 4H) ppm. LC / MS: 462.1 [M+H]+.

[0249] Example 21 Preparation of ((S)-cyclopropyl(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indole-2-carbonyl)indoline-6-yl)(imino)-λ6-sulfonone): Example 21 was obtained as the second eluent during the chiral SFC purification of Example 19 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO‑d6): δ 8.64 (d, J = 4.4Hz, 1H), 8.56 (d, J = 6.5Hz, 1H), 7.96‑7.83 (m, 4H), 7.38‑7.30 (m, 3H), 4.53 (s) , 1H) , 4.33 (br t , J = 8.4Hz, 2H) , 3.73 (quin , J = 8.0Hz, 1H) , 3.31 - 3.20 (m, 6H) , 2.78 (br d , J = 4.9Hz, 1H) , 1.06 - 0.90 (m, 4H) ppm. LC / MS: 462.1 [M+H]+.

[0250] Example 22 Preparation of ((5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indoline-6-yl)(methyl)(methylimino)-16-sulfonone): Specification 52 / 60 pages 59 CN 122206672 A Example 22 was prepared using general procedure A (step one only), with intermediates 1 and 8 as starting materials. 1H NMR (400MHz, DMSO-d6): δ 8.64 (br d, J = 4.0Hz, 1H), 8.55 (d, J = 6.6Hz, 1H), 7.95-7.83 (m, 4H), 7.40-7.30 (m, 3H), 4.34 (br t, J = 8.5Hz, 2H) , 3.73 (quin, J = 8.0Hz, 1H) , 3.33- 3.26 (m, 6H), 3.19 (s, 3H), 2.47 (s, 3H) ppm. LC / MS: 450.1 [M+H]+.

[0251] Example 23 Preparation of ((R)-(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indoline-6-yl)(methyl)(methylimino)-λ6-sulfonone): Example 23 was obtained as the first eluent during chiral SFC purification of Example 22 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO‑d6): δ 8.64 (d, J = 4.8Hz, 1H), 8.54 (d, J = 6.6Hz, 1H), 7.96‑7.83 (m, 4H), 7.41‑7.30 (m, 3H), 4.34 (t , J = 8.5Hz, 2H), 3.73 (quin, J = 8.0Hz, 1H), 3.32-3.23 (m, 6H), 3.19 (s, 3H), 2.46 (s, 3H) ppm. LC / MS: 450.1 [M+H]+.

[0252] Example 24 Preparation of ((S)-(5-fluoro-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indoline-6-yl)(methyl)(methylimino)-λ6-sulfonone): Example 24 was obtained as the second eluent during the chiral SFC purification of Example 22 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO‑d6): δ 8.64 (br d , J = 4 .5Hz , 1H) , 8.54 (d , J = 6 .5Hz , 1H) , 7 .96 ‑ 7 .83 (m , 4H) , 7 .41 ‑ 7 .30 (m , 3H) , 4.34 (br t, J = 8.4Hz, 2H) , 3.78 - 3.69 (m , 1H) , 3.28 (br d, J = 8.0Hz, 6H) , 3.18 (s, 3H) , 2.46 (s, 3H) ppm. LC / MS: 450.1 [M+H]+.

[0253] Example 25Preparation of (ethyl(5-fluoro-2-methyl-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indololin-6-yl)(imino)-λ6-sulfonone): See specification 53 / 60 pages 60 CN 122206672 A. Example 25 was prepared using general procedure A, with intermediates 1 and 7 as starting materials. 1H NMR (400 MHz, DMSO-d6): δ 8.64 (br s, 1H), 8.60–8.52 (m, 1H), 7.99–7.83 (m, 4H), 7.43–7.26 (m, 3H), 4.96–4.83 (m, 1H), 4.58 (d ,J= 17.5Hz, 1H) , 3.75 (quin ,J= 8.3Hz, 1H) , 3.52 (br dd ,J= 8.9, 16.8Hz, 1H) , 3.47 ‑ 3.35 (m , 2H) , 3.30 ‑ 3.18 (m, 3H) , 3.17 ‑ 3.06 (m, 1H) , 2.81 (br d,J= 16.9Hz, 1H) , 1.29 (br d,J= 6.1Hz, 3H) , 1.10 (br t,J= 7.2Hz, 3H) ppm. LC / MS: 464.2 [M+H]+.

[0254] Example 26 Preparation of ((R)-ethyl((R)-5-fluoro-2-methyl-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indole-2-carbonyl)indololin-6-yl)(imino)-λ6-sulfonone): Example 26 was obtained as the first eluent during the chiral SFC purification of Example 25 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO‑d6): δ 8.64 (d, J = 4.0Hz, 1H), 8.55 (d, J = 6.6Hz, 1H), 8.01‑7.81 (m, 4H), 7.39 (d, J = 9.7Hz, 1H), 7.35 - 7.27 (m, 2H) , 4.96 - 4.82 (m, 1H) , 4.60 (s, 1H) , 3.75 (quin , J = 8.1Hz, 1H) , 3.52 (br dd , J = 8.7 , 16.9Hz, 1H) , 3.46 - 3.36 (m, 2H) ,3.31 ‑ 3.17 (m, 3H) , 3.11 (br dd , J = 7.7, 16.0Hz, 1H) , 2.81 (br d , J = 16.7Hz, 1H) , 1.29 (d , J = 6.2Hz, 3H) , 1.10 (t, J = 7.3Hz, 3H) ppm. LC / MS: 464.2 [M+H]+.

[0255] Example 27 Preparation of ((S)-ethyl((R)-5-fluoro-2-methyl-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indole-2-carbonyl)indoline-6-yl)(imino)-λ6-sulfonone): Example 27 was obtained as the second eluent during the chiral SFC purification of Example 25 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO‑d6): δ 8.64 (d, J = 4.0Hz, 1H), 8.56 (d, J = 6.6Hz, 1H), 8.02‑7.78 (m, 4H), 7.39 (d, J = 9.8Hz, 1H), 7.36 - 7.28 (m, 2H) , 4.96 - 4.80 (m, 1H) , 4.56 (s, 1H) , 3.81 - 3.69 (m, 1H) , 3.52 (br dd , J = 9.0, 16.7Hz, 1H) , 3.46 - 3.36 (m, 2H), 3.29 - 3.18 (m, 3H), 3.11 (br dd, J = 7.4, 15.8Hz, 1H), 2.81 (br d, J = 17.0Hz, 1H), 1.29 (d, J = 6.2Hz, 3H), 1.10 (t , J = 7.3Hz, 3H) ppm. LC / MS: 464.2 [M+H]+.

[0256] Example 28 Preparation of ((S)-ethyl((S)-5-fluoro-2-methyl-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indoline-6-yl)(imino)-λ6-sulfonone): Example 28 was prepared using ChiralPak IH (250×30mm×10µm) and 50% co-solvent (0.1% NH3 / methanol).It was obtained as the third elution buffer during the chiral SFC purification of Example 25. 1H NMR (400MHz, DMSO‑d6): δ 8.63 (d, J = 4.0Hz, 1H), 8.56 (d, J = 6.6Hz, 1H), 7.96‑7.81 (m, 4H), 7.44‑7.28 (m, 3H), 4.95‑ 4.83 (m, 1H) , 4.57 (s, 1H) , 3.81 ‑ 3.70 (m, 1H) , 3.58 ‑ 3.34 (m, 3H) , 3.28 ‑ 3.08 (m, 4H) , 2.81 (br d, J = 17.0Hz, 1H) , 1.29 (br d, J = 6.1Hz, 3H), 1.11 (t, J = 7.3Hz, 3H) ppm. LC / MS: 464.2 [M+H]+.

[0257] Example 29 Preparation of ((R)-ethyl((S)-5-fluoro-2-methyl-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indole-2-carbonyl)indoline-6-yl)(imino)-λ6-sulfonone): Example 29 was obtained as the fourth eluent during the chiral SFC purification of Example 25 using ChiralPak IH (250×30mm×10µm) and 50% cosolvent (0.1% NH3 / methanol). 1H NMR (400MHz, DMSO‑d6): δ 8.64 (br d , J = 4.5Hz, 1H) , 8.57 (br d , J = 6.6Hz, 1H) , 7.98‑ 7.78 (m, 4H) , 7.44‑ 7.27 (m, 3H) , 4.95 ‑ 4.82 (m, 1H) , 4.53 (s, 1H) , 3.81 ‑ 3.69 (m, 1H) , 3.58 ‑ 3.34 (m, 3H) , 3.27 ‑ 3.09 (m, 4H) , 2.81 (br d , J = 17.1Hz, 1H) , 1.29 (br d, J = 6.0Hz, 3H), 1.10 (br t, J = 7.3Hz, 3H) ppm. LC / MS: 464.2 [M+H]+.

[0258] Example 30 Preparation of ((R)-N-ethyl-5-fluoro-1-(5-(pyridin-2-yl)-2,3-dihydro-1H-indene-2-carbonyl)indoline-6-sulfonamide): The preparation of Example 30 was carried out using general procedure A (step one only), with intermediates 1 and 9 as starting materials.30. ¹H NMR (400MHz, DMSO-d⁶): δ 8.64 (dd, J = 0.8, 4.8Hz, 1H), 8.53 (d, J = 6.6Hz, 1H), 7.96–7.83 (m, 4H), 7.77 (br t, J = 5.4Hz, 1H), 7.40–7.29 (m, 3H), 4.34 (t, J = 8.5Hz, 2H), 3.78–3.68 (m, 1H), 3.32–3.20 (m, 6H), 2.93–2.80 (m, 2H). (Note: The last part of the original text appears to be a reference to a metric or index and is left untranslated.) 0.98 (t,J= 7.2Hz, 3H) ppm. LC / MS: 466.0 [M+H]+.

[0259] Example 31 Preparation of ((R)-N-ethyl-5-fluoro-1-(5-(pyridin-2-yl)-2,3-dihydrobenzofuran-2-carbonyl)indoline-6-sulfonamide): Example 31 was prepared using general procedure A (step 1 only), with intermediates 2 and 9 as starting materials. 1H NMR (400MHz, DMSO-d6): δ 8.60 (br d, J = 4.4Hz, 1H), 8.48 (d, J = 6.6Hz, 1H), 8.00 (s, 1H), 7.92–7.80 (m, 4H), 7.41 (br d, J = 9.8Hz, 1H), 7.30–7.24 (m, 1H) , 6.94 (d , J = 8.3Hz, 1H) , 5.74 (br dd , J = 7.1 , 9.0Hz, 1H) , 4.46 ‑ 4.26 (m, 2H) , 3.67 ‑ 3.53 (m, 2H) , 3.31 (br s, 2H) , 2.86 (quin, J = 6.7Hz, 2H) , 0.97 (t, J = 7.2Hz, 3H) ppm. LC / MS: 468.0 [M+H]+.

[0260] Example 32 Preparation of (N-(((R)-5-fluoro-2-methyl-1-((R)-5-(pyridin-2-yl)-2,3-dihydro-1H-indole-2-carbonyl)indoline-6-yl)sulfonyl)butyramide): Specification 56 / 60 pages 63 CN 122206672 A Intermediate 32.7 was prepared according to the procedure described in PCT application No. PCT / US2023 / 022679.

[0261] Preparation of intermediate 32.1: 5-fluoro-2-methylindoline (40 g, 268 mmol, 1 equivalent) was dissolved in acetic acid (200 mL, 5V). NaBH3CN (50 g, 815 mmol, 3 equivalent) was added in portions while maintaining the temperature below 10°C. The resulting solution was heated to room temperature and stirred for 3 hours, during which time the reaction was diluted with ice-cold water (500 mL). The reaction was then extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine (750 mL), dried over Na2SO4, and concentrated under vacuum. Crude intermediate 32.1 was separated as a thick, yellow oil, and this crude intermediate could be used in the next step without further purification. LC / MS: 151.2 [M+H]+.

[0262] Preparation of intermediate 32.2: Triethylamine (35 mL, 1 volume) was added to a stirred solution of intermediate 32.1 (35 g, 86.6 mmol) in DCM (300 mL) at 0 °C, followed by the addition of acetyl chloride (35 mL, 1 volume). The reaction mixture was stirred at room temperature for 2 hours. The residue was quenched with cold water (200 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine (750 mL), dried over Na2SO4, and concentrated under vacuum. The crude residue was purified by column chromatography (100 to 200 silica gel, eluted with 8% EtOAc-hexane) to give intermediate 32.2. LC / MS: 193.2 [M+H]+.

[0263] Preparation of intermediate 32.3: At 0°C and under nitrogen, intermediate 32.2 (35 g, 0.011 mol) was added to a stirred solution in chlorosulfonic acid (250 mL, 10 V), and the reaction mixture was stirred at 50°C for 3 hours. After the reaction was complete, the mixture was diluted with ice-cold water. The precipitate was filtered, dissolved in dichloromethane (50 mL), and added to a concentrated ammonium hydroxide solution (20 mL). After vigorous stirring at room temperature for 15 minutes, the solvent was removed under pressure, and the resulting solid was filtered and washed with water to obtain intermediate 32.3. LC / MS: 272.3 [M+H]+.

[0264] Preparation of intermediate 32.4: The racemic mixture of intermediate 32.3 (30 g, 110 mmol, 1 equivalent) in 500 mL of 2N sodium hydroxide was heated at 100 °C for 3 hours. The reaction was cooled to room temperature, and the pH was adjusted to 7 with acetic acid. The precipitate was filtered, washed with water, and dried under vacuum. The resulting deacetylated racemic mixture was then purified by chiral SFC using a ChiralPak IG 240 × 4.6 mm column with a mobile phase of 70:20:10 hexane:methanol:MTBE. Intermediate32.4 was collected as the second eluent (retention time 13.1 min). LC / MS: 230.1 [M+H]+.

[0265] Intermediate 32.4 was dissolved in THF (10V) and dimethylformamide dimethyl acetal (1.2 equivalents) was added in one step. The solution was stirred at room temperature for 30 min, and then the solvent was removed under reduced pressure to obtain crude residue intermediate 32.5 (LC / MS: 286.1 [M+H]+), which was used directly in the next step without further purification.

[0266] Intermediate 32.5 was dissolved in acetonitrile (10V). Intermediate 1 (1 equivalent) was added, followed by TCFH (2 equivalents). The suspension was placed in a water bath at room temperature and N-methylimidazole (5 equivalents) was added dropwise. The solution was stirred at room temperature for 1 hour, at which point LC / MS analysis indicated complete conversion to intermediate 32.6 (LC / MS: 507.2 [M+H]). Then add hydrazine hydrate (50 equivalents) all at once and stir the solution at room temperature for 30 minutes, after which add water (5V). The resulting precipitate was filtered and dried under reduced pressure to give intermediate 32.7. ¹H NMR (400MHz, DMSO-d6): δ 8.69 (d, J = 4.9Hz, 1H), 8.54 (d, J = 6.6Hz, 1H), 8.10–7.84 (m, 4H), 7.58 (s, 2H), 7.51–7.24 (m, 3H), 4.90 (t, J = 7.5Hz, 1H), 3.77 (p, J = 8.2Hz, 1H), 3.46 (ddt, J = 34.0, 17.5, 8.7Hz, 3H), 3.20 (ddd, J = 59.1, 16.3, 8.3Hz, 2H), 2.80 (d, J = 16.9Hz, 1H), 1.30 (d, J = 6.2Hz, 3H) ppm. LC / MS: 452.1 [M+H]+.

[0267] Intermediate 32.7 (250 mg, 0.55 mmol) was dissolved in THF (5 mL), and triethylamine (112 mg, 2 equivalents), DMAP (14 mg, 0.2 equivalents), and n-butyric anhydride (88 mg, 1.0 equivalents) were added at room temperature. After 1 hour, silica gel (5 g) was added, and the solvent was removed under reduced pressure. The resulting free-flowing solid was purified by rapid column chromatography (0% to 20% methanol / DCM) to obtain Example 32. ¹H NMR (400MHz, DMSO): δ 12.38 (s, ¹H), 8.82–8.49 (m, δ 1H), δ 8.82–8.49 (m, δ 1H).2H), 7.98 (s, 1H), 7.97-7.83 (m, 3H), 7.43 (d,J= 9.9Hz, 1H), 7.37-7.28 (m, 2H), 4.90 (p,J= 6.7Hz, 1H), 3.76 (p,J= 8.3Hz, 1H) , 3.66 ‑ 3.48 (m, 1H) , 3.42 (ddd,J= 16.1, 8.3, 3.1Hz, 2H) , 3.27 (dd,J= 15.9, 8.6Hz, 1H) , 3.14 (dd,J= 16 .1, 7.8Hz, 1H), 2.83 (d, J = 17.1 Hz, 1H), 2.22 (t, J = 7.2 Hz, 2H), 2.08 (s, 1H), 1.44 (h, J = 7.3 Hz, 2H), 1.30 (d, J = 6.3 Hz, 3H), 0.78 (t, J = 7.4 Hz, 3H) ppm. LC / MS: 522.2 [M+H]+.

[0268] Bioassays HSV-2 Cell Omics Assays The ability of compounds to inhibit HSV-2 replication was tested by monitoring the expression of HSV protein gD using a high-throughput immunofluorescence-based assay. Ten doses, three-fold serial dilutions of the compounds were prepared in 100% DMSO at starting concentrations of 0.2 mM or 2 mM. Using a Labcyte ECHO acoustic dispenser, 250 nmol of the compound was applied in quadruplicate to 384-well microplates (Greiner catalog number 781956) with a transparent black collagen coating. The final starting concentration for the assay was 1 μM or 10 μM. DMSO (compound-free) and prepirenzeb were added to each well as negative and positive controls, respectively.

[0269] ARPE-19 cells (ATCC catalog number CRL-2302) were maintained in DMEM / F-12 Glutamax medium (Thermo manual 58 / 60 pages 65 CN 122206672 A Fisher Scientific catalog number 10565018) supplemented with 10% FBS (Corning catalog number 35-011-CV) and 1% penicillin-streptomycin (catalog number 30-002-CI). Before confluence, the cells were transferred to centrifuge tubes and centrifuged at 1000 rpm for 5 minutes. Cells were resuspended in assay medium (DMEM / F-12 Glutamax, 2% FBS, 1% penicillin-streptomycin).Cells were counted in 50 ml conical tubes at an MOI of 0.06. The cell density was adjusted to 150,000 cells / ml and HSV-2 virus (MS strain, ATCC catalog number VR-540) was infected for 1 hour with constant shaking. The cells were then centrifuged at 1000 rpm for 5 minutes and the medium was replaced with assay medium containing 2% FBS or 10% human serum (EMD Millipore catalog number S1-100ML). 50 μl of the infection suspension was added to the wells of a microplate pre-spotted with the compound (7,500 cells / well). The plate was incubated at 37°C for 16 hours.

[0270] Cell culture medium was aspirated using Biomek Fx and 50 μl of paraformaldehyde solution (Electron Microscopy Sciences catalog number 15712-S) diluted to 4% in DPBS (Corning catalog number 21-031-CM) was added to each well. After incubating at room temperature for 30 minutes, the plate was washed four times with 100 μl / well of PBS using a Biotek plate washer. A 1:500 solution of primary antibody (anti-HSV gD, Virusys catalog number P1103) was prepared in permeabilization buffer (Invitrogen catalog number 00-8333-56), and 50 μl was added to each well. After incubating at room temperature for 1 hour, 50 μl of a 1:1000 solution of secondary antibody (Alexa Fluor 488 goat anti-mouse, Thermo Fisher Scientific catalog number A11001) and DAPI (Thermo Fisher Scientific catalog number 62248) in permeabilization buffer was added to each well, and the plate was incubated at room temperature in the dark for 1 hour. The plate was washed four times again, and 50 μl of DPBS was added to all wells. The plate was then sealed with a black adhesive strip. Fluorescence was measured using a Cellomics plate reader.

[0271] Data analysis was performed using Thermo Scientific HCS Studio software. In short, cells were identified using DAPI nuclear staining and a threshold was set to filter cells based on shape and size. A second threshold was set based on green fluorescence intensity (detecting HSV-2 gD) to identify HSV-2-infected cells. Data were reported as the mean fluorescence intensity of HSV-2-infected cells. The EC50 value was defined as the concentration of the compound that caused a 50% reduction in mean fluorescence intensity and was calculated using a curve fitting generated by an S-type dose-response model. In this assay, the EC50 for prerenvironmentally active drugs was 150 nM. Data for some compounds are reported in Table 1 below.

[0272] Table 1: Specification 59 / 60 pages 66 CN 122206672 AUnless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0273] Therefore, it should be understood that although this disclosure has been specifically disclosed by way of preferred embodiments and optional features, modifications, improvements and variations of the disclosure implemented herein may be adopted by those skilled in the art, and such modifications, improvements and variations are considered to be within the scope of this disclosure. The materials, methods and embodiments provided herein represent preferred embodiments, are exemplary, and are not intended to limit the scope of this disclosure.

[0274] This disclosure has been described broadly and generally herein. Each narrower group of species and subgenus falling within the general disclosure also forms part of this disclosure. This includes the general description of this disclosure, from which any subject matter is removed, whether or not specifically described herein.

[0275] In addition, where features or aspects of this disclosure are described according to the Markush Group, those skilled in the art will recognize that this disclosure is also described according to any individual member or subgroup of the Markush Group.

[0276] It should be understood that although this disclosure has been described in conjunction with the above embodiments, the foregoing description and embodiments are intended to illustrate and not limit the scope of this disclosure. Other aspects, advantages, and modifications within the scope of this disclosure will be apparent to those skilled in the art to which this disclosure pertains. Specification 60 / 60 pages 67 CN 122206672 A

Claims

1. A compound of formula (I): (I) Or its pharmaceutically acceptable salt, wherein R 1 for , or ; R 2a R 2b and R 2c Each is independently H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, -CN, C 1-6 Halogenated alkoxy groups or -SCF3; R 3a and R 3b Each is independently H, halogen, C 1-6 Alkyl or C 1-6 Halogenated alkyl groups; X a and X b Each is independently O or CR 7a R 7b ; Each R 7a Independently for H and C 1-6 Alkyl or C 1-6 Halogenated alkyl groups; Each R 7b Independently for H and C 1-6 Alkyl or C 1-6 Halogenated alkyl groups; R 4a R 4b and R 4c Each is independently H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, -CN, -SCF3, or optionally Z 4 Replacement C 3-6 cycloalkyl; R 5 C 6-10 aryl or heteroaryl; wherein R 5 The aryl or heteroaryl groups are optionally separated by one to three Z groups that are identical or different. 5 Replace; R 5 The heteroaryl group is a 5- to 10-membered heteroaryl group having one to three heteroatoms, each of which is independently N, O, or S; R 6 For H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-8 Alkoxyalkyl or C 3-6 cycloalkyl, wherein R 6 The cycloalkyl group is optionally surrounded by one to three Z 6 replace; R 8 For NHR 9 or NR 9 R 10 ; Each R 9 R 10 and R 12 Independently for C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, -COR 9a Or C 3-6 cycloalkyl; R 9 R 10 Or R 12 The alkyl or cycloalkyl groups are optionally selected from one to three independently selected from -OR 12a and -SR 12a Substitution of groups; R 11 For H, C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, -COR 9a Or C 3-6 cycloalkyl; R 11 The alkyl or cycloalkyl group is optionally surrounded by one to three independently -OR 12a or -SR 12a Substitution of groups; Each R 13 and R 14 Independently H or C 1-6 alkyl; R 15 C 1-6 Alkyl, C 1-6 Halogenated alkyl or C 3-6 cycloalkyl; R 15 The alkyl or cycloalkyl group is optionally surrounded by one to three independently -OR 12a or -SR 12a Substitution of groups; Each R 9a and R 12a Independently for C 1-6 Alkyl; and Each Z 4 Z 5 and Z 6 Independent of halogen, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Halogenated alkoxy groups; The condition is that when R 11 When it is H, R 12 Not -CH3.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (Ia): (It)。 3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (II): (II)。 4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIa): (IIa)。 5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (III): (III)。 6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIIa): (IIIa)。 7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIIb): (IIIb)。 8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIIc): (IIIc)。 9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIId): (IIId).

10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is represented by formula (IIIe): (IIIe) 11. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R 2a For H.

12. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and 11, wherein R 2b It is a halogen.

13. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and 11, wherein R 2b It is F.

14. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and 11 to 13, wherein R 2c For H.

15. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 and 11 to 14, wherein R 3a For H.

16. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 and 11 to 15, wherein R 3b For H.

17. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and 11 to 16, wherein R 4a For H.

18. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and 11 to 17, wherein R 4b For H.

19. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 and 11 to 18, wherein R 4c For H.

20. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 and 11 to 22, wherein R 5 It is a heteroaryl group; in which R 5 The heteroaryl group can optionally be replaced by one to three Z groups that are the same or different. 5 replace.

21. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 and 11 to 20, wherein R 5 To be optionally defined by one to three Z that are the same or different 5 Substituted pyridinyl group.

22. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 and 11 to 21, wherein R 5 It is pyridyl.

23. The compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R 6 For H, C 1-6 Alkyl or C 1-6 Halogenated alkyl groups.

24. The compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein R 6 For H.

25. The compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt thereof, wherein R 6 It is -CH3.

26. The compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R 1 for .

27. The compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R 1 for ; R 8 For NHR 9 or NR 9 R 10 ; Each R 9 and R 10 Independently for C 1-6 Alkyl, C 1-6 Halogenated alkyl groups, -COR 9a Or C 3-6 cycloalkyl; R 9 Or R 10 The C mentioned 1-6 Alkyl optional -OR 12a Replace; and Each R 9a and R 12a Independently for C 1-6 alkyl.

28. The compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R 1 for ; R 8 For NHR 9 ; R 9 C 1-6 Alkyl or -COR 9a ;and R 9a C 1-6 alkyl.

29. The compound according to any one of claims 1 to 28, or a pharmaceutically acceptable salt thereof, wherein R 1 for or .

30. The compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R 1 for .

31. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 25, wherein... R 1 for ; R 11 For H; R 12 -CH2OR 12a C 2-6 Alkyl, C 1-6 Halogenated alkyl or C 3-6 cycloalkyl; R 12 The alkyl or cycloalkyl group is optionally -OR 12a Replace; and R 12a C 1-6 alkyl.

32. The compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R 1 for ; R 11 For H; R 12 C 2-6 Alkyl or C 3-6 cycloalkyl; R 12 The alkyl or cycloalkyl group is optionally -OR 12a Replace; and R 12a C 1-6 alkyl.

33. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 25 and 30 to 32, wherein R 1 for , , or .

34. The compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein... R 1 for ; R 11 C 1-6 alkyl; R 12 C 1-6 Alkyl, C 1-6 Halogenated alkyl or C 3-6 cycloalkyl; R 12 The alkyl or cycloalkyl group is optionally -OR 12a Replace; and R 12a C 1-6 alkyl.

35. The compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, wherein R 1 for ; R 11 C 1-6 alkyl; R 12 C 1-6 Alkyl or C 3-6 cycloalkyl; R 12 The alkyl or cycloalkyl group is optionally -OR 12a Replace; and R 12a C 1-6 alkyl.

36. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 25, 30, 34 and 35, wherein R 1 for .

37. A compound listed in Table 1 or a pharmaceutically acceptable salt thereof.

38. A compound listed in Table 1 or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a mixture of stereoisomers thereof.

39. A pharmaceutical composition comprising a compound according to any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

40. The pharmaceutical composition of claim 39, wherein the pharmaceutical composition further comprises one, two, three or four additional therapeutic agents.

41. The pharmaceutical composition of claim 40, wherein the additional therapeutic agent is selected from famciclovir, acyclovir, and valacyclovir.

42. A method of treating herpes virus infection, the method comprising administering to a patient a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38, or administering to a patient in need a therapeutically effective amount of the composition according to any one of claims 39 to 41.

43. The method of claim 42, wherein the method comprises administering a compound of any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof, or a composition of any one of claims 39 to 41, in combination with one, two, three, or four additional therapeutic agents.

44. The method according to claim 42 or 43, wherein the herpesvirus is HSV-1 or HSV-2.

45. A method for treating a disorder induced, aggravated, or accelerated by a herpesvirus, the method comprising administering to a patient a therapeutically effective amount of a compound according to any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof, or administering to a patient in need a therapeutically effective amount of a composition according to any one of claims 39 to 41.

46. ​​The method of claim 45, wherein the method comprises administering a compound of any one of claims 1 to 38 or a pharmaceutically acceptable salt thereof, or a composition of any one of claims 39 to 41, in combination with one, two, three, or four additional therapeutic agents.

47. The method of claim 45 or 46, wherein the obstacle is genital herpes, cold herpes, HSV keratitis, HSV encephalitis, or disseminated HSV.

48. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 in the treatment of viral infections.

49. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 in the treatment of viral infections caused by herpesviruses.

50. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 in the treatment of viral infections caused by HSV-1 or HSV-2.

51. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 in the preparation of a medicament for the prevention / treatment of viral infections.

52. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 in the preparation of a medicament for the prevention / treatment of viral infections caused by herpesviruses.

53. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38 for the preparation of a medicament for the prevention / treatment of viral infections caused by HSV-1 or HSV-2.

54. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38, or the pharmaceutical composition according to any one of claims 39 to 41, wherein the compound or a pharmaceutically acceptable salt thereof or the pharmaceutical composition is used in a method of treating viral infections caused by HSV-1 or HSV-2.

55. The compound, its pharmaceutically acceptable salt, or pharmaceutical composition used according to claim 54, wherein the viral infection is genital herpes, cold sores, HSV keratitis, HSV encephalitis, or disseminated HSV.

56. The compound, its pharmaceutically acceptable salt, or pharmaceutical composition used according to claim 54 or 55, wherein the compound or its pharmaceutically acceptable salt is administered in combination with an additional therapeutic agent.

57. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 38, wherein the compound or a pharmaceutically acceptable salt thereof is used in a therapeutic manner.